EP2295630A1 - Method for producing coated protein fibres - Google Patents
Method for producing coated protein fibres Download PDFInfo
- Publication number
- EP2295630A1 EP2295630A1 EP09170024A EP09170024A EP2295630A1 EP 2295630 A1 EP2295630 A1 EP 2295630A1 EP 09170024 A EP09170024 A EP 09170024A EP 09170024 A EP09170024 A EP 09170024A EP 2295630 A1 EP2295630 A1 EP 2295630A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- fibers
- protein fibers
- solution
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 245
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 245
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 239000000835 fiber Substances 0.000 claims abstract description 193
- 238000000034 method Methods 0.000 claims abstract description 62
- 230000008569 process Effects 0.000 claims abstract description 25
- -1 2-cyanoacrylic acid ester Chemical class 0.000 claims abstract description 23
- 239000006185 dispersion Substances 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical class OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 claims description 24
- 238000001523 electrospinning Methods 0.000 claims description 22
- 238000009987 spinning Methods 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 11
- 238000006731 degradation reaction Methods 0.000 claims description 11
- 230000009471 action Effects 0.000 claims description 8
- 239000004745 nonwoven fabric Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 230000010534 mechanism of action Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 41
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 36
- 229920000642 polymer Polymers 0.000 description 29
- 208000027418 Wounds and injury Diseases 0.000 description 15
- 206010052428 Wound Diseases 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 12
- 239000004744 fabric Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 10
- 239000012460 protein solution Substances 0.000 description 10
- 238000001878 scanning electron micrograph Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 108010067770 Endopeptidase K Proteins 0.000 description 7
- 229920001872 Spider silk Polymers 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000002121 nanofiber Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920001651 Cyanoacrylate Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 230000005684 electric field Effects 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229920003176 water-insoluble polymer Polymers 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000004830 Super Glue Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Chemical class 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002303 citric acid monohydrate Drugs 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920005594 polymer fiber Polymers 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004753 textile Substances 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000239290 Araneae Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003905 agrochemical Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- CFUNAYGQFFNNSD-UHFFFAOYSA-L ferrous ammonium sulfate heptahydrate Chemical compound [NH4+].[NH4+].O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O CFUNAYGQFFNNSD-UHFFFAOYSA-L 0.000 description 2
- 238000007380 fibre production Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 108010019116 resilin Proteins 0.000 description 2
- 229920002781 resilin Polymers 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 238000002166 wet spinning Methods 0.000 description 2
- ZDEIQGWACCNREP-UHFFFAOYSA-N 1-azido-2,3,4,5,6-pentafluorobenzene Chemical compound FC1=C(F)C(F)=C(N=[N+]=[N-])C(F)=C1F ZDEIQGWACCNREP-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150082901 ADF3 gene Proteins 0.000 description 1
- 101150003973 ADF4 gene Proteins 0.000 description 1
- 241000228431 Acremonium chrysogenum Species 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000193935 Araneus diadematus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000186226 Corynebacterium glutamicum Species 0.000 description 1
- ZGERHCJBLPQPGV-ACZMJKKPSA-N Cys-Ser-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N ZGERHCJBLPQPGV-ACZMJKKPSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- FTIJVMLAGRAYMJ-MNXVOIDGSA-N Gln-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(N)=O FTIJVMLAGRAYMJ-MNXVOIDGSA-N 0.000 description 1
- WSDOHRLQDGAOGU-BQBZGAKWSA-N His-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 WSDOHRLQDGAOGU-BQBZGAKWSA-N 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RENBRDSDKPSRIH-HJWJTTGWSA-N Ile-Phe-Met Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)O RENBRDSDKPSRIH-HJWJTTGWSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- MEYVLGVRTYSQHI-UHFFFAOYSA-L cobalt(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Co+2].[O-]S([O-])(=O)=O MEYVLGVRTYSQHI-UHFFFAOYSA-L 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229940053009 ethyl cyanoacrylate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RDBMUARQWLPMNW-UHFFFAOYSA-N phosphanylmethanol Chemical class OCP RDBMUARQWLPMNW-UHFFFAOYSA-N 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F4/00—Monocomponent artificial filaments or the like of proteins; Manufacture thereof
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/18—Formation of filaments, threads, or the like by means of rotating spinnerets
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F11/00—Chemical after-treatment of artificial filaments or the like during manufacture
- D01F11/02—Chemical after-treatment of artificial filaments or the like during manufacture of cellulose, cellulose derivatives, or proteins
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/345—Nitriles
- D06M13/348—Nitriles unsaturated, e.g. acrylonitrile
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/02—Natural fibres, other than mineral fibres
- D06M2101/10—Animal fibres
- D06M2101/12—Keratin fibres or silk
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2200/00—Functionality of the treatment composition and/or properties imparted to the textile material
- D06M2200/10—Repellency against liquids
- D06M2200/12—Hydrophobic properties
Definitions
- the present invention relates to processes for the production of coated protein fibers in which from a solution or dispersion of a protein fibers having a diameter in the range of 10 nm to 10 microns are produced. Furthermore, the invention relates to coated protein fibers, their use and fiber fabrics comprising the coated protein fibers.
- nano- and mesofibers ie fibers with a diameter of a few nm to a few microns
- electrospinning or centrifugal spinning process to name just a few.
- Methods for electrospinning are also known to those skilled in the art and described in the literature, for example in DH Reneker and HD Chun, Nanotechn. 7 (1996) 216 f , and A. Greiner and J. Wendorff, Angew. Chemistry Int. Ed.
- Electrospinning processes for the production of protein fibers are described, for example, in the non-prepublished EP 09156540.8 (File reference) and EP 08162122.9 (File reference) described.
- Centrifuge spinning processes suitable for the production of nanofibers are described, for example, in US Pat EP 624 665 A and the EP 1 088 918 A disclosed.
- the polymer-containing solution or dispersion is placed in a rotating container and discharged by centrifugal forces from the container in the form of fibers.
- the fibers obtained by means of these electrospinning or centrifuge spinning processes can also be deposited and obtained directly, for example by deposition on a support, in the form of fibrous sheets, for example nonwovens.
- polymer and protein fibers are widely used, for example in mass applications such as textiles, as technical devices such as filters or, in the case of protein fibers, for special applications such as wound dressings in the medical sector.
- fibrous webs such as fabrics or nonwovens.
- These are widely used, for example in mass applications such as textiles, as technical devices such as filters or, in the case of protein fibers, for special applications such as wound dressings in the medical sector.
- polymers based on protein or polysaccharide which also do not dissolve under the action of water, but can absorb and incorporate water, so that produced from these polymers fibers or surface fiber structure, for example, swell and thus also in their mechanics or - in particular in filters - be changed in their permeability.
- fibers from water-soluble polymers can be rendered insoluble by cross-linking or restructuring (post-crystallization).
- the stability of polyvinyl alcohol fibers against water could be achieved, for example, by treatment with methanol (see Yao L. et al., Chem. Mater. 15 (2003) 1860-1864 ), Crosslinking with polyacrylic acid (see Zeng J. et al., E-polymers 78 (2004 )) or UV crosslinking of modified polyvinyl alcohol (see Zeng J. et al., Macromol. Rapid Commun. 26 (2005) 1557-1562 ) increase.
- the crosslinker was already added to the polymer-containing spinning solution and co-spun. It is a thermal or radiation-induced treatment required, which is usually complex and expensive.
- a chemical cross-linker is understood to mean a molecule in which at least two chemically reactive groups are connected to one another via a linker.
- sulfhydryl-reactive groups for example maleimides, pyridyl disulfides, ⁇ -haloacetyls, vinyl sulfones, sulfatoalkyl sulfones (preferably sulfatoethyl sulfones)
- amine-reactive groups for example succinimidyl esters, carbodiimde, hydroxymethyl phosphine, imido esters, PFP esters, aldehydes, isothiocyanates etc.
- carboxy-reactive groups eg, amines, etc.
- hydroxyl-reactive groups eg, isocyanates, etc.
- unselective groups eg, aryl azides, etc.
- photoactivatable groups eg, perfluorophenyl azide, etc.
- the WO 2006/089522 A1 discloses methods of making polymer fibers wherein a dispersion of a water-insoluble polymer is electrospun in an aqueous medium.
- a dispersion of a water-insoluble polymer is electrospun in an aqueous medium.
- One way to improve the water stability of fibers obtained from aqueous dispersions by electrospinning of water-insoluble polymers consists in the interparticle crosslinking of the fibers according to WO 2009/074630 , another in the targeted tuning of glass transition temperature of the polymer and processing temperature in electrospinning according to WO 2009/010443 ,
- poly-2-cyanoacrylate fibers have also been described, in that monomer vapors were deposited on a substrate and polymerized with initiator (see FIG. SV Doiphode et al., Polymer 47 (12) (2006) 4328-4332 ).
- the adhesion and adhesion of 2-cyanoacrylates or their polymers, as well as their relatively low water solubility are known in the art.
- 2-cyanoacrylates or their polymers for bonding wounds for improving the adhesion of polymer films (s. Dong YW et al., J. Adhesion Sci. Technol. 9 (4) (1995) 501-525 ) and used as so-called superglue.
- organic solvents should, if possible, be largely avoided in the production of such water- or moisture-stable fibers and fibrous webs for toxicological, occupational safety and regulatory reasons.
- coated protein fibers and fiber webs which can be produced by the process according to the invention have improved water or moisture resistance compared with known nanofibers, ie. they have a reduced solubility, swelling and / or change in the mechanical properties and / or the flow properties and / or the fiber structure and / or an improved decomposition or degradation behavior under the action of moisture or moisture.
- organic solvents is largely avoided in the inventive method.
- all proteins can be used in the method according to the invention, which are known from the solution or dispersion according to those skilled in the art and described in the literature to fibers having a diameter in the range of 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, especially preferably from 50 nm to 2 microns, let process.
- Suitable proteins in the context of the present invention are synthetic or natural proteins, including peptides, in particular amphiphilic self-assembling proteins, where the proteins may optionally additionally be chemically and / or enzymatically modified, for example by esterification, amidation, saponification, carboxylation, acetylation, acylation, Hydroxylation, glycosylation or farnesylation.
- Preferred proteins for use in the processes according to the invention are those which are not water or moisture-resistant, in particular those which are water-soluble or water swellable.
- water-soluble is understood as meaning all proteins whose solubility in water at 23 ° C. is higher than 0.1% by weight (based on the total weight of the solution).
- all proteins are to be understood as "water-swellable” whose weight increase after 6 hours storage at 50 ° C. in a circulating air oven and subsequent storage in water at 23 ° C. for more than 30 minutes is more than 1% (based on the weight of the protein after 6 hours storage at 50 ° C).
- amphiphilic self-assembling proteins are, for example, microbead-forming proteins as described in US Pat WO-A-20077082936 or in the WO-A-2008155304 which is hereby incorporated by reference, or intrinsically unfolded proteins.
- the amphiphilic self-assembling protein is a silk protein, such as, in particular, a spider silk protein, preferably a C16 protein (see SEQ ID NO: 2,); or a spinnable protein derived from these proteins having a sequence identity of at least about 50%, e.g. at least 60, 70, 80, 90, 95, 96, 97, 98 or 99%.
- R16 protein comprising an amino acid sequence of SEQ ID NO: 4 or the S16 protein comprising an amino acid sequence of SEQ ID NO: 6; or a spinnable protein derived from these proteins having a sequence identity of at least about 60%, e.g. at least 70, 80, 90, 95, 96, 97, 98 or 99%.
- Silicon proteins are understood to mean those proteins which contain highly repetitive amino acid sequences and are stored in the animal in a liquid form and whose secretion by shearing or spinning results in fibers ( Craig, CL (1997) Evolution of arthropod silks. Annu. Rev. Entomol. 42: 231-67 ).
- Particularly suitable proteins are spider silk proteins which could be isolated in their original form from spiders.
- Especially suitable proteins are silk proteins that could be isolated from the spider's "major ampullate” gland.
- Preferred silk proteins are ADF3 and ADF4 from the "major ampullate" gland of Araneus diadematus ( Guerette et al., Science 272, 5258: 112-5 (1996 )).
- suitable proteins are natural or synthetic proteins derived from natural silk proteins and which, using genetic engineering techniques, are heterologous in prokaryotic or eukaryotic expression systems were manufactured.
- prokaryotic expression organisms are Escherichia coli, Bacillus subtilis, Bacillus megaterium, Corynebacterium glutamicum and others.
- Nonlimiting examples of eukaryotic expression organisms are yeasts such as Saccharomyces cerevisiae, Pichia pastoris and others, filamentous fungi such as Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans, Trichoderma reesei, Acremonium chrysogenum and others, mammalian cells such as Hela cells, COS cells, CHO Cells, etc., insect cells, such as Sf9 cells, MEL cells and others.
- synthetic proteins based on repeating units of natural silk proteins.
- these may additionally contain one or more natural non-repetitive silk protein sequences ( Winkler and Kaplan, J. Biotechnol 74: 85-93 (2000 )).
- synthetic spider silk proteins preferred for the formulation of drugs by means of spinning processes are synthetic spider silk proteins which are based on repeating units of natural spider silk proteins.
- synthetic repetitive spider silk protein sequences these may additionally contain one or more natural non-repetitive spider silk protein sequences.
- C16 protein Huemmerich et al. Biochemistry, 43 (42): 13604-13612 (2004 )
- This protein has the polypeptide sequence shown in SEQ ID NO: 2.
- polypeptide sequence shown in SEQ ID NO: 2 particularly functional equivalents, functional derivatives and salts of this sequence are also preferred.
- R16 and S16 proteins Particularly preferred among the combination proteins of silk proteins and resilins are the R16 and S16 proteins. These proteins have the polypeptide sequences shown in SEQ ID NO: 4 and SEQ ID NO: 6.
- polypeptide sequences shown in SEQ ID NO: 4 and SEQ ID NO: 6 particularly functional equivalents, functional derivatives and salts of these sequences are also preferred.
- “functional equivalents” are understood in particular also to mean mutants which are present in at least one sequence position of the abovementioned amino acid sequences have another than the specifically mentioned amino acid but still has the property for packaging effect substances.
- “Functional equivalents” thus include the mutants obtainable by one or more amino acid additions, substitutions, deletions, and / or inversions, which changes can occur in any sequence position as long as they result in a mutant having the property profile of the invention. Functional equivalence is especially given when the reactivity patterns between mutant and unchanged polypeptide are qualitatively consistent.
- Precursors are natural or synthetic precursors of the polypeptides with or without the desired biological activity.
- salts means both salts of carboxyl groups and acid addition salts of amino groups of the protein molecules according to the invention.
- Salts of carboxyl groups can be prepared in a manner known per se and include inorganic salts such as sodium, calcium, ammonium, iron and zinc salts, as well as salts with organic bases such as amines such as triethanolamine, arginine, lysine , Piperidine and the like.
- Acid addition salts such as, for example, salts with mineral acids, such as hydrochloric acid or sulfuric acid, and salts with organic acids, such as acetic acid and oxalic acid, are likewise provided by the invention.
- “Functional derivatives” of polypeptides of the invention may also be produced at functional amino acid side groups or at their N- or C-terminal end by known techniques.
- Such derivatives include, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups prepared by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups prepared by reaction with acyl groups.
- homologs to the specific proteins / polypeptides disclosed herein. These have at least 60%, e.g. 70, 80 or 85%, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity to one of the specifically disclosed amino acid sequences.
- identity between two sequences is meant, in particular, the identity of the residues over the respective entire sequence length, in particular the identity which can be determined by comparison with Vector NTI Suite 7.1 (Vector NTI Advance 10.3.0, Invitrogen Corp.) (or Software The company Informax (USA) using the Clustal method (Higgins DG, Sharp PM, Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl. Biosci.
- Gap opening penalty 10 Gap extension penalty 0.05
- Residue specific gaps off Hydrophilic residues gap off Transition weighing 0
- Pairwise alignment parameter FAST algorithm off K-tuple size 1 Gap penalty 3 Window size 5
- the said proteins can also be used in admixture with one or more polymers, for. B as a dispersant or thickener for the spinnable solution.
- the mixing ratios are basically no limits, but usually such mixtures include 10 to 99 wt .-%, preferably 50 to 99 wt .-%, particularly preferably 80 to 99 wt.
- wt .-% protein and 1 to 90 wt .-%, preferably 1 to 50 wt .-%, particularly preferably 1 to 20 wt .-%, of one or more polymers, wherein the wt .-% are each based on the total weight of Protein and polymer and together give 100 wt .-%.
- polymers encompasses both homopolymers and copolymers, with the exception of proteins. Suitable copolymers are both random and alternating systems, block copolymers or graft copolymers.
- copolymers encompasses polymers which are made up of two or more different monomers or in which the incorporation of at least one monomer into the polymer chain can be realized in various ways, e.g. in the case of stereo block copolymers. Blends of homopolymers and copolymers can also be used. The homo- and copolymers may be miscible or immiscible with each other.
- polymers which are suitable for the processes according to the invention can be of synthetic origin, but they can also be naturally occurring polymers, for example based on polysaccharides.
- Suitable polymers include, for example, polyvinyl alcohol, poly-N-vinylpyrrolidone, polyvinylformamide, polyethylene oxide, polyvinylamine, polyvinyl acetate, polyacrylic acid, polyacrylic acid esters, polyacrylamide, polyaccharides such as cellulose, cellulose ethers such as e.g.
- Methylcellulose (with a degree of substitution of from 3 to 40%), ethylcellulose, butylcellulose, hydroxymethylcelluloses; hydroxyethylcelluloses; Hydroxypropylcelluloses, isopropylcellulose, cellulose esters, e.g. Cellulose acetate, starches, modified starches, e.g. Methyl ether starch, alginate.
- electrospinning or centrifuge spinning processes in particular electrospinning processes.
- Methods for electrospinning are, for example, in DH Reneker and HD Chun, Nanotechn. 7 (1996) 216 f ., A. Greiner and J. Wendorff, Angew. Chemistry Int. Ed. 119 (2007) 5770-5805 .
- WO 2009/010443 described.
- the solution to be used in electrospinning can be electrospun in any manner known to those skilled in the art.
- the solution to be spun is placed in an electric field with a thickness of generally between 0.01 and 10 kV / cm, preferably between 1 and 6 kV / cm and particularly preferably between 2 and 4 kV / cm, introduced by being squeezed out of one or more cannulas under low pressure.
- the mass transport in the form of a jet takes place on the opposite electrode.
- the possibly present solvent evaporates in the interelectrode space and the proteinaceous solid is then present in the form of fibers on the counter electrode.
- Spinning can be done in both vertical directions (bottom to top and top to bottom) and in horizontal direction.
- a cylinder-based device for example Nanospider from Elmarco (Czech Rep.), Is used.
- the solution used is in a container in which a metal roller rotates permanently or the spin formulation is metered onto the roller with a separate device.
- the roll can be smooth, structured or provided with metal wires. In this case, part of the formulation is resistant to the roll surface.
- the electric field between the roller and the counterelectrode (above the roller) causes only liquid jets to form from the formulation, which then lose any solvent present or solidify the melt on the way to the counterelectrode.
- a nanofiber nonwoven fabric is formed on the substrate (eg polypropylene, polyester or cellulose), which is passed between the two electrodes.
- the electric field generally has a strength between 0.01 to 10 kV / cm, preferably between 1 and 6 kV / cm and more preferably between 2 and 4 kV / cm.
- the electric field has a magnitude of 2.1 kV / cm (82 kV at 25 cm electrode spacing). Spinning can be done in both vertical directions (bottom to top and top to bottom) and in horizontal direction.
- Additives may be added to the solution or dispersion of the protein to alter, for example, the viscosity or surface tension, resulting in e.g. selectively influence the fiber formation or fiber morphology.
- Preferred additives are thickeners and surfactants known to the person skilled in the art and described in the literature.
- active substances which have a targeted effect on a living organism, in particular a pharmacological, agrochemical, medicinal or cosmetic effect.
- active substances may be active pharmaceutical ingredients, cosmetic effect substances, agrochemical active substances (fungicides, herbicides, insecticides), food or feed additives, biological active substances (peptides, growth factors, bacteria) or a combination of several of these active substances.
- agrochemical active substances fungicides, herbicides, insecticides
- food or feed additives biological active substances (peptides, growth factors, bacteria) or a combination of several of these active substances.
- the type or formulation of the active ingredients, their amounts and concentrations to be used as well as the targeted specific action in the living organism are known to those skilled in the art as such and described in the literature (see, for example WO 2001/54667 . WO 2004/014304 .
- WO 2007/082936 WO 2007/093232 , and the unpublished EP 09156540.8 (File reference) and EP 08162122.9 (File number)).
- amounts of active substance of from 0.01 to 80% by weight, preferably from 1 to 70% by weight, particularly preferably from 10 to 50% by weight, based in each case on the total weight of protein and active ingredient, used.
- the aim of the addition of the active substances mentioned is that they are released or released after the application of the coated protein fibers or fiber fabrics according to the invention on or on living organisms, and specifically develop a desired specific action on or in the living organism.
- the fibers which can be prepared from the solution or dispersion of a protein by the abovementioned processes generally have a diameter in the range from 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, particularly preferably from 50 nm to 2 .mu.m.
- Essential to the invention is that these fibers are contacted during or after their preparation with a 2-cyanoacrylic acid ester.
- Suitable 2-cyanoacrylic acid esters which are generally known to the person skilled in the art and are described in the literature, are, for example, methyl, ethyl, n-butyl, octyl, allyl or methoxyethyl esters of 2-cyanoacrylic acid, in particular ethyl 2-cyanoacrylate.
- the contacting of the protein fibers can be carried out according to the invention by exposing the fibers to an atmosphere containing gaseous 2-cyanoacrylates during their production.
- the partial pressure of 2-cyanoacrylates in the gas phase is equal to or less than the vapor pressure of the 2-cyanoacrylic ester used at the respective processing temperature.
- the partial pressure of the 2-cyanoacrylic esters used is generally in the range of 1 mbar to 1 bar, preferably in the range of 50 mbar to 800 mbar, more preferably in the range of 100 mbar to 500 mbar.
- the partial pressures of the 2-cyanoacrylic acid esters used can also be significantly higher than these values.
- the contacting of the protein fibers with gaseous 2-cyanoacrylic acid ester is preferably carried out by exposing the fibers to an atmosphere containing gaseous 2-cyanoacrylic acid esters after their preparation. That In a first step, the protein fibers are prepared according to the methods described above, and only in a second separate step is the contacting of the protein fibers with gaseous 2-cyanoacrylic acid ester.
- the advantage of this variant is that the temperature-dependent vapor pressures of 2-cyanoacrylates can be chosen independently of the temperature of the protein fiber production.
- the partial pressure of the 2-cyanoacrylic esters used is generally in the range of 1 mbar to 1 bar, preferably in the range of 50 mbar to 800 mbar, more preferably in the range of 100 mbar to 500 mbar.
- the partial pressures of the 2-cyanoacrylic acid esters used can also be significantly higher than these values.
- the contacting of the protein fibers with gaseous 2-cyanoacrylic acid both during and after their preparation is usually carried out over a period of 1 s to 60 min, preferably from 10 s to 30 min, more preferably from 1 min to 10 min.
- the contacting of the protein fibers with 2-cyanoacrylic esters can also be effected by adding the 2-cyanoacrylic acid esters already to the solution or dispersion of the protein from which the protein fibers are produced (of course, this embodiment is not possible if the ingredients the solution or dispersion chemically react with the 2-cyanoacrylates or cause their polymerization, which is the case for example with aqueous solutions).
- the concentration of 2-cyanoacrylic acid ester in the solution or dispersion in this embodiment of the invention is usually in the range of 0.1 to 10 wt .-%, preferably from 0.5 to 5 wt .-%, particularly preferably from 1 to 5 wt. -%, in each case based on the total weight of the solution or dispersion.
- the contacting of the protein fibers with 2-cyanoacrylic acid ester can also be effected by treating the fibers after their preparation with a solution containing the 2-cyanoacrylic acid esters.
- suitable Solvents for 2-cyanoacrylic acid esters are, for example, acetone or 2-butanone.
- the concentration of 2-cyanoacrylic acid esters in this solution is usually in the range from 0.1 to 10% by weight, preferably from 0.5 to 5% by weight, particularly preferably from 1 to 5% by weight, in this embodiment of the invention. , in each case based on the total weight of the solution.
- the temperature at which the contacting takes place is usually in the range from 5 to 90 ° C., preferably from 15 to 50 ° C., particularly preferably from 18 to 30 ° C.
- the contacting of the protein fibers with the solution of the 2-cyanoacrylic esters is generally carried out over a period of 1 s to 60 min, preferably from 10 s to 30 min, more preferably from 1 min to 10 min.
- the contacting of the protein fibers with 2-cyanoacrylic acid ester is preferred, in which the fibers are exposed after or during their production to an atmosphere containing gaseous 2-cyanoacrylic acid esters.
- the described coatings of the protein fibers with 2-cyanoacrylic acid ester are not limited to the fibers as such, but can also be carried out accordingly on the fibrous webs formed from the protein fibers.
- the protein fibers which can be produced in the course of the process according to the invention have a diameter in the range from 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, particularly preferably from 50 nm to 2 .mu.m.
- the length of the fibers depends on the purpose and is usually 50 microns to several kilometers.
- monomeric 2-cyanoacrylate precipitates and is polymerized to poly-2-cyanoacrylates.
- the deposition is usually carried out in the form of an adhering to the protein fiber, particularly preferably complete, coating.
- the coating can also be partial, i. E. the surface of the protein fibers is not completely coated.
- the poly-2-cyanoacrylates formed are not or only partially adhere to the fiber in the form of a coating, but instead adhere to or in the fiber or on the fiber.
- the coated protein fibers according to the invention can be prepared by the processes according to the invention.
- Preferred inventive coated protein fibers comprising protein fibers having a diameter in the range of 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, more preferably from 50 nm to 2 .mu.m, and a coating of poly-2-cyanoacrylic acid ester adhering to the protein fibers the thickness of the coating is particularly preferably in the range from 1 to 200 nm, in particular from 10 to 100 nm.
- coated protein fibers according to the invention are particularly suitable for the production of fibrous sheets.
- the preparation of the fiber fabrics can be carried out either in the same process step as the production of protein fibers, for example as described above in the direct production of fiber fabrics by electrospinning, or in a separate process step known in the art and described in the literature following the preparation the coated protein fibers of the invention.
- fibrous sheets according to the invention can be used in numerous different fields of application, for example for the production of nonwovens or nonwovens, in particular nonwovens for use in cosmetic products, textiles, in particular household textiles, cleaning products, medical products (such as wound dressings or face masks), hygiene products such as diapers, incontinence products , Panty liners, sanitary napkins, tampons, skin and facial pads, and the like, cell culture carriers.
- the objects mentioned may consist wholly or only partially of the fiber fabrics, z. B in the form of coatings and / or components.
- the fibrous sheets according to the invention are preferably used as filters and medical carriers.
- Particularly preferred fiber sheets are used as wound care and wound care products, wound dressings, plasters, tamponades, wound dressings, bandages, dressings.
- they can be used to superficially cover minor wounds such as cuts or larger wounds such as diabetic wounds, ulcers such as pressure sores, surgical wounds, burns, eczema, and the like.
- fibrous sheets according to the invention can be used in the treatment of bleeding or non-bleeding wounds or injuries in the area of the skin, the eyes, the ears, the nose, the oral cavity, the teeth, as well as in the interior of the body, such as surgery in the intestinal region (stomach, intestine, Liver, kidneys, urinary tract), thorax (heart, lungs), genital area, skull, musculature; in the treatment and aftercare of wounds related to the transplantation of tissues, vessels or organs.
- intestinal region stomach, intestine, Liver, kidneys, urinary tract
- thorax heart, lungs
- genital area skull, musculature
- coated protein fibers and fiber fabrics produced by the process according to the invention have improved water or moisture resistance compared with known nanofibers, ie they have reduced solubility, swelling and / or change in mechanical properties and / or flow properties under water or moisture. or the fiber structure and / or an improved decomposition or degradation behavior.
- the use of organic solvents is largely avoided in the inventive process if possible.
- a further advantage of the coated protein fibers according to the invention is that polymerized 2-cyanoacrylic acid esters are harmless from a medical or toxicological point of view (see, for example, US Pat Handbook of Adhesive Technology, 2nd Ed., A. Pizzi, K. Mittal, Marcel Decker (Ed.), 2003, p. 809 ) and for many applications, for example in the medical sector.
- the protein fibers described in the Examples were prepared by the following either tip-based or roller-based electrospinning techniques. Further specific details are given in the individual examples.
- a capillary nozzle connected to one pole of a power source is used to atomize the protein dispersion or solution.
- a square counterelectrode connected to the other pole of the voltage source is arranged at a distance of about 20 cm, which acts as a collector for the fibers formed.
- a voltage between 15 kV and 35 kV is set at the electrodes and the protein dispersion or solution is discharged through the capillary nozzle under a low pressure.
- coated protein fibers according to the invention were contacted either with gaseous or dissolved in a solvent 2-Cyanacrylklaestern. Further specific details are given in the individual examples.
- the protein fibers and coated protein fibers according to the invention prepared according to the examples and comparative examples were introduced into quiescent water at a temperature of 23 ° C. for a period of 24 hours to determine the resistance to water or moisture. After subsequent drying, electron or light micrographs were taken. By comparing them visually with corresponding electron or light micrographs of the identical protein fiber samples prior to water treatment, it can be seen whether and how much the fibers, their morphology or microstructure has changed under the action of water, i. how water- or moisture-resistant the fibers are.
- the protein used was a protein S16.
- S16 protein microbeads were used to prepare spinnable S16 protein solutions. These can be like in WO 2008/155304 be prepared described. Alternatively, a production may be carried out as follows. The production of the S16 protein is carried out biotechnologically using plasmid-containing Escherichia coli expression strains (plasmid vectors or E. coli production strains were used which contained coding DNA sequences for the S16 protein). Design and cloning of the S16 protein are analogous to Hümmerich et al. (Biochemistry 43, 2004, 13604-13012 ) feasible. In contrast to the method described there, S16 protein was produced in E. coli strain BL21 Gold (DE3) (Stratagene).
- Minimal medium 2.5 g / l citric acid monohydrate 4 g / l glycerol 12.5 g / l potassium dihydrogen phosphate 6.25 g / l ammonium sulfate 1.88 g / l of magnesium sulfate heptahydrate 0.13 g / l calcium chloride dihydrate 15.5 ml / l of trace element solution (40 g / l citric acid monohydrate; 11 g / l zinc (II) sulphate heptahydrate; 8.5 g / l diammonium iron (II) sulphate heptahydrate; 3 g / l manganese (II) sulphate monohydrate; 0.8 g / l copper (II) sulphate pentahydrate; 0.25 g / l cobal
- the pellet was resuspended in 20 mM 3 - (- N-morpholino) propanesulfonic acid (MOPS) pH 7.0 (5 L buffer per kilogram wet weight). Subsequently, cell digestion was carried out using a Micofluidizer M-110EH (Microfluidics, US) at pressures of 1200 to 1300 bar. After sedimentation, the pellet contained after digestion in addition to the "inclusion bodies" cell debris and membrane components, which were removed by two washing steps.
- MOPS propanesulfonic acid
- the pellet was resuspended in 2.5 volumes Tris buffer (50 mM Tris / HCl, 0.1% Triton X-100, pH 8.0), and then the remaining solid was sedimented by centrifugation. A second wash was performed using Tris buffer (50 mM Tris / HCl, 5 mM EDTA, pH 8.0). The pellet, once again obtained after sedimentation, was almost free of membrane and cell debris.
- Tris buffer 50 mM Tris / HCl, 0.1% Triton X-100, pH 8.0
- inclusion bodies were dissolved in guanidinium thiocyanate (Roth, Germany), 1.6 g guanidinium thiocyanate being added per 1 g pellet (wet mass).
- the inclusion bodies were dissolved with gentle heating (50 ° C.) with stirring. To separate off any non-soluble constituents, a centrifugation was then carried out. In order to obtain an aqueous S16 protein solution, dialysis was then carried out for 16 hours against 5 mM potassium phosphate buffer (pH 8.0) (dilution factor of dialysis: 200).
- Contaminating E. coli proteins formed aggregates on dialysis, which could be separated by centrifugation.
- the resulting protein solution had a purity of ⁇ 95% S16 protein.
- the aqueous protein solution was processed by precipitation to protein microbeads.
- the aqueous S16 protein solution was admixed with 0.25 parts by volume of a 4 molar ammonium sulfate solution. Under the action of the ammonium sulfate, the protein monomers assemble into spherical structures, which are referred to here as microbeads.
- the microbeads were separated by centrifugation, washed three times with distilled water and then freeze-dried.
- Example V-1 The protein fibers thus obtained (Example V-1) are in Fig. 1 shown.
- Example V-1 A part of the protein fibers obtained in Example V-1 was tested for water and moisture resistance as described above.
- Fig. 2 shows these protein fibers after the test.
- Example V-1 Another portion of the protein fibers obtained in Example V-1 was contacted with ethyl 2-cyanoacrylate as follows:
- Example 1 0.2 g of ethyl-2-cyanoacrylate from Sigma Aldrich were placed in a glass vial with a volume of 10 ml and then brought into the gas phase at a temperature of 150-170 ° C, ie evaporated. Subsequently, the substrate with the protein fibers obtained in Example V-1 was left in this for a period of 1 minute Gas phase contacted.
- the coated protein fibers (Example 1) thus obtained are described in Fig. 3 shown.
- Example 1 A part of the coated protein fibers obtained in Example 1 was tested for water and moisture resistance as described above.
- Fig. 4 shows these coated protein fibers after the test.
- the protein S16 described in Examples V-1 and 1 was used as the protein and processed into protein fibers in the manner also described in Examples V-1 and 1.
- Example 2 0.1 g of ethyl 2-cyanoacrylate was dissolved in 9.9 g of toluene. Subsequently, the substrate was contacted with the protein fibers obtained in Example 2 for a period of 10 seconds with this toluenic ethyl-2-cyanoacrylate solution and finally dried.
- the coated protein fibers (Example 2) thus obtained are described in Fig. 5 shown.
- Example 2 A part of the coated protein fibers obtained in Example 2 was tested for water and moisture resistance as described above.
- Fig. 6 shows these coated protein fibers after the test.
- the protein used was a protein R16.
- Example V-3 The protein fibers thus obtained (Example V-3) are described in Fig. 7 shown.
- Example V-3 A part of the protein fibers obtained in Example V-3 was tested for water and moisture resistance as described above.
- Fig. 8 shows these protein fibers after the test.
- Example V-3 Another portion of the protein fibers obtained in Example V-3 was contacted with ethyl 2-cyanoacrylate as follows:
- Example 3 0.2 g of ethyl-2-cyanoacrylate from Sigma Aldrich were placed in a glass vial with a volume of 10 ml and then brought into the gas phase at a temperature of 150-170 ° C, ie evaporated. Subsequently, the substrate was contacted with the protein fibers obtained in Example V-3 for a period of 1 minute in this gas phase.
- the coated protein fibers (Example 3) thus obtained are described in Fig. 9 shown.
- Example 3 A part of the coated protein fibers obtained in Example 3 was tested for water and moisture resistance as described above.
- Fig. 10 shows these coated protein fibers after the test.
- R16 protein fibers were prepared as described in Example V-3.
- the R16 protein fibers not contacted with ethyl 2-cyanoacrylate showed clearly visible degradation or dissolution phenomena in the proteinase K mixtures even after 120 min. After 24 h, the non-ethyl 2-cyanoacrylate contacted R16 protein fibers (Example V-4a) were visually almost completely degraded ( Figure 11A ). The ethyl 2-cyanoacrylate contacted R16 protein fibers (Examples 4c and d) were still intact in the proteinase K inserts even after 24 h and had not dissolved ( FIGS. 11C and D ), or in the case of the 20 s ethyl 2-cyanoacrylate contacted R16 protein fibers (Example 4 b) showed relatively low signs of degradation after 24 h ( FIG. 11B ).
- coated protein fibers and fiber fabrics produced by the process according to the invention have improved water or moisture resistance compared to known nanofibers, ie they have a reduced solubility, swelling and / or change in the mechanical properties under water or moisture. or the flow properties and / or the fiber structure and / or an improved decomposition or degradation behavior.
Landscapes
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Nonwoven Fabrics (AREA)
- Artificial Filaments (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft Verfahren zur Herstellung von beschichteten Proteinfasern, bei denen aus einer Lösung oder Dispersion eines Proteins Fasern mit einem Durchmesser im Bereich von 10 nm bis 10 µm hergestellt werden. Weiterhin betrifft die Erfindung beschichtete Proteinfasern, deren Verwendung sowie Faserflächengebilde umfassend die beschichteten Proteinfasern.The present invention relates to processes for the production of coated protein fibers in which from a solution or dispersion of a protein fibers having a diameter in the range of 10 nm to 10 microns are produced. Furthermore, the invention relates to coated protein fibers, their use and fiber fabrics comprising the coated protein fibers.
Verfahren zur Herstellung von Polymerfasern sind in der Literatur beschrieben und dem Fachmann bekannt (s. beispielsweise
Die Herstellung von sogenannten Nano- und Mesofasern, d.h. Fasern mit einem Durchmesser von wenigen nm bis einigen µm, lässt sich besser auf andere Weise durchführen, beispielsweise nach Elektrospinn- oder Zentrifugenspinnverfahren, um nur einige davon zu nennen.
Verfahren zum Elektrospinnen sind dem Fachmann ebenfalls bekannt und in der Literatur beschrieben, beispielsweise in
Elektrospinnverfahren zur Herstellung von Proteinfasern werden beispielsweise in den nicht vorveröffentlichten
Zur Herstellung von Nanofasern geeignete Zentrifugenspinnverfahren sind beispielsweise in
Die nach diesen Elektrospinn- oder Zentrifugenspinnverfahren erhaltenen Fasern können in der Regel auch direkt, beispielsweise durch Abscheidung auf einem Träger, in Form von Faserflächengebilden, beispielsweise Vliesen, abgeschieden und erhalten werden.The production of so-called nano- and mesofibers, ie fibers with a diameter of a few nm to a few microns, can be performed better in other ways, for example by electrospinning or centrifugal spinning process, to name just a few.
Methods for electrospinning are also known to those skilled in the art and described in the literature, for example in
Electrospinning processes for the production of protein fibers are described, for example, in the non-prepublished
Centrifuge spinning processes suitable for the production of nanofibers are described, for example, in US Pat
As a rule, the fibers obtained by means of these electrospinning or centrifuge spinning processes can also be deposited and obtained directly, for example by deposition on a support, in the form of fibrous sheets, for example nonwovens.
Eines der Haupteinsatzgebiete für Polymer- und Proteinfasern ist die Herstellung von Faserflächengebilden wie Gewebe oder Vliese. Diese finden verbreiteten Einsatz, beispielsweise in Massenanwendungen wie Textilien, als technische Vorrichtungen wie Filter oder auch -im Fall der Proteinfasern - für spezielle Anwendungen wie Wundabdeckungen im medizinischen Sektor. Für die meisten Anwendungen dieser Art ist es wichtig, daß die Polymer- bzw. Proteinfasern eine gute Wasser- bzw. Feuchtigkeitsstabilität aufweisen. Diese ist normalerweise nicht gegeben, wenn die Faser aus wasserlöslichen Polymeren, z.B. Polyvinylalkohol, hergestellt wurde. Aber auch gemeinhin als wasserunlöslich bezeichnete Polymere haben oftmals den Nachteil, daß aus ihnen hergestellte Faserflächengebilde zumindest bei längerer Einwirkung von Wasser bzw. Feuchtigkeit an Stabilität oder Festigkeit verlieren können. So gibt es beispielsweise natürlich vorkommende Polymere auf Protein- oder Polysaccharidbasis, die sich zwar unter Wassereinwirkung ebenfalls nicht lösen, die aber Wasser aufnehmen und einbauen können, so daß aus diesen Polymeren hergestellte Fasern oder Flächenfasergebilde beispielsweise aufquellen und somit ebenfalls in ihrer Mechanik oder - insbesondere bei Filtern - in ihrer Durchlässigkeit verändert werden.One of the main fields of application for polymer and protein fibers is the production of fibrous webs such as fabrics or nonwovens. These are widely used, for example in mass applications such as textiles, as technical devices such as filters or, in the case of protein fibers, for special applications such as wound dressings in the medical sector. For most applications of this type, it is important that the polymer or protein fibers have good water and moisture stability, respectively. This is normally not the case when the fiber is made from water soluble polymers, eg polyvinyl alcohol. But also commonly referred to as water-insoluble polymers often have the disadvantage that fiber fabrics made from them can lose stability or strength, at least for prolonged exposure to water or moisture. For example, there are naturally occurring polymers based on protein or polysaccharide, which also do not dissolve under the action of water, but can absorb and incorporate water, so that produced from these polymers fibers or surface fiber structure, for example, swell and thus also in their mechanics or - in particular in filters - be changed in their permeability.
Zur Verbesserung der Wasser- bzw. Feuchtigkeitsbeständigkeit von Polymer- bzw. Proteinfasern oder daraus hergestellter Faserflächengebilde sind in der Literatur diverse Maßnahmen beschrieben.To improve the water or moisture resistance of polymer or protein fibers or fiber fabrics produced therefrom, various measures are described in the literature.
So können Fasern aus wasserlöslichen Polymeren durch Vernetzung oder Umstrukturierung (Nachkristallisation) unlöslich gemacht werden. Die Stabilität von Polyvinylalkoholfasern gegen Wasser konnte z.B. durch Behandlung mit Methanol (siehe
Spezielle Proteine können zum einen mit Hilfe von physikalischen Methoden wie Lösemittelbehandlung oder Druckbehandlung wasserstabiler gemacht werden. Dies geschieht laut
Die
Auch die Bildung von Poly-2-cyanacrylat-Fasern ist beschrieben, und zwar indem Monomerdämpfe auf ein Substrat abgeschieden und mit Initiator zur Polymerisation gebracht wurden (s.
Trotz dieser bekannten Verfahren sind günstigere und effizientere Methoden wünschenswert, um die Wasser- bzw. Feuchtigkeitsbeständigkeit von Polymer- bzw. Proteinfasern, insbesondere der sogenannten Nanofasern, zu verbessern. Weiterhin ist es wünschenswert, die Zersetzung bzw. den Abbau von Proteinfasern, wie er beispielsweise durch Enzyme oder Mikroorganismen in Anwesenheit von Feuchtigkeit oder Wasser erfolgen kann, zu beeinflußen, d.h. je nach Anwendung der Proteinfasern entweder zu beschleunigen oder zu verlangsamen; beispielsweise wäre es wünschenswert, Proteinfasern als Wundabdeckungen einzusetzen, wobei die durch Wundenzyme bedingten Zersetzungs- bzw. Abbauraten der Proteinfasern gezielt einstellbar sind. Aufgabe der vorliegenden Erfindung ist es daher, Proteinfasern, insbesondere sogenannte Nanofasern, und daraus erhältlich Faserflächengebilde bereit zu stellen, die eine verbesserte Wasser- bzw. Feuchtigkeitsbeständigkeit aufweisen, d.h. unter Wasser- bzw. Feuchtigkeitseinwirkung eine verringerte Löslichkeit, Quellung und/oder Veränderung der mechanischen Eigenschaften und/oder der Durchflußeigenschaften und/oder der Faserstruktur oder ein verbessertes Zersetzungs- bzw. Abbauverhalten aufweisen. Die Verwendung organischer Lösungsmittel sollte bei der Herstellung solcher wasser- bzw. feuchtigkeitsstabileren Fasern und Faserflächengebilde aus toxikologischen, arbeitssicherheitsbedingten und zulassungsrechtlichen Gründen wenn möglich weitgehend vermieden werden.Despite these known methods, more favorable and more efficient methods are desirable in order to improve the water or moisture resistance of polymer or protein fibers, in particular the so-called nanofibers. Furthermore, it is desirable to influence the decomposition or degradation of protein fibers, as can be done for example by enzymes or microorganisms in the presence of moisture or water, ie either accelerate or slow down depending on the application of protein fibers; For example, it would be desirable to use protein fibers as wound coverings, whereby the decomposition or degradation rates of the protein fibers caused by the wound enzymes are specifically adjustable. It is therefore an object of the present invention to provide protein fibers, in particular so-called nanofibers, and fiber fabrics obtainable therefrom, which have improved resistance to water or moisture, ie a reduced solubility, swelling and / or change in the mechanical properties under the action of water or moisture Have properties and / or the flow properties and / or the fiber structure or an improved decomposition or degradation behavior. The use of organic solvents should, if possible, be largely avoided in the production of such water- or moisture-stable fibers and fibrous webs for toxicological, occupational safety and regulatory reasons.
Diese Aufgabe wird durch die eingangs genannten Verfahren gelöst, wobei erfindungswesentlich ist, daß die Fasern während oder nach ihrer Herstellung mit einem 2-Cyanacrylsäureester kontaktiert werden.This object is achieved by the method mentioned, wherein essential to the invention is that the fibers are contacted during or after their preparation with a 2-cyanoacrylic.
Die nach den erfindungsgemäßen Verfahren herstellbaren beschichteten Proteinfasern sowie Faserflächengebilde besitzen gegenüber bekannten Nanofasern eine verbesserte Wasser- bzw. Feuchtigkeitsbeständigkeit, d.h. sie weisen unter Wasser- bzw. Feuchtigkeitseinwirkung eine verringerte Löslichkeit, Quellung und/oder Veränderung der mechanischen Eigenschaften und/oder der Durchflußeigenschaften und/oder der Faserstruktur und/oder ein verbessertes Zersetzungs- bzw. Abbauverhalten auf. Die Verwendung organischer Lösungsmittel wird bei den erfindungsgemäßen Verfahren weitgehend vermieden.The coated protein fibers and fiber webs which can be produced by the process according to the invention have improved water or moisture resistance compared with known nanofibers, ie. they have a reduced solubility, swelling and / or change in the mechanical properties and / or the flow properties and / or the fiber structure and / or an improved decomposition or degradation behavior under the action of moisture or moisture. The use of organic solvents is largely avoided in the inventive method.
Die erfindungsgemäßen Gegenstände, Verfahren und Verwendungen werden im Folgenden beschrieben.The articles, methods and uses of the invention are described below.
Grundsätzlich können in den erfindungsgemäßen Verfahren alle Proteine eingesetzt werden, die sich aus Lösung oder Dispersion nach dem Fachmann bekannten und in der Literatur beschriebenen Verfahren zu Fasern mit einem Durchmesser im Bereich von 10 nm bis 10 µm, bevorzugt von 20 nm bis 5 µm, besonders bevorzugt von 50 nm bis 2 µm, verarbeiten lassen.In principle, all proteins can be used in the method according to the invention, which are known from the solution or dispersion according to those skilled in the art and described in the literature to fibers having a diameter in the range of 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, especially preferably from 50 nm to 2 microns, let process.
Geeignete Proteine im Rahmen der vorliegenden Erfindung sind synthetische oder natürliche Proteine, einschließlich Peptiden, wie insbesondere amphiphile selbstassemblierenden Proteine, wobei die Proteine gegebenenfalls zusätzlich chemisch und/oder enzymatisch modifiziert sein können, beispielsweise durch Veresterung, Amidierung, Verseifung, Carboxylierung, Acetylierung, Acylierung, Hydroxylierung, Glycosylierung oder Farnesylierung.Suitable proteins in the context of the present invention are synthetic or natural proteins, including peptides, in particular amphiphilic self-assembling proteins, where the proteins may optionally additionally be chemically and / or enzymatically modified, for example by esterification, amidation, saponification, carboxylation, acetylation, acylation, Hydroxylation, glycosylation or farnesylation.
Bevorzugte Proteine zum Einsatz in den erfindungsgemäßen Verfahren sind solche, die nicht wasser- bzw. feuchtigkeitsbeständigkeit sind, insbesondere solche, die wasserlöslich oder wasserquellbar sind. Im Rahmen der vorliegenden Erfindung sind als "wasserlöslich" alle Proteine zu verstehen, deren Löslichkeit in Wasser bei 23°C höher als 0,1 Gew.-% ist (bezogen auf das Gesamtgewicht der Lösung). Im Rahmen der vorliegenden Erfindung sind als "wasserquellbar" alle Proteine zu verstehen, deren Gewichtszunahme nach 6-stündiger Lagerung bei 50°C im Umluftschrank und anschließender 30-minütiger Lagerung in Wasser bei 23°C mehr als 1 % beträgt (bezogen auf das Gewicht des Proteins nach der 6-stündigen Lagerung bei 50°C).Preferred proteins for use in the processes according to the invention are those which are not water or moisture-resistant, in particular those which are water-soluble or water swellable. For the purposes of the present invention, "water-soluble" is understood as meaning all proteins whose solubility in water at 23 ° C. is higher than 0.1% by weight (based on the total weight of the solution). In the context of the present invention, all proteins are to be understood as "water-swellable" whose weight increase after 6 hours storage at 50 ° C. in a circulating air oven and subsequent storage in water at 23 ° C. for more than 30 minutes is more than 1% (based on the weight of the protein after 6 hours storage at 50 ° C).
Die bevorzugten amphiphilen selbstassemblierenden Proteine sind z.B. Microbeadbildende Proteine, wie sie in der
Beispielsweise ist das amphiphile selbstassemblierende Protein ein Seidenprotein, wie insbesondere ein Spinnenseidenprotein, vorzugsweise ein C16-Protein (vgl. SEQ ID NO: 2,); oder ein von diesen Proteinen abgeleitetes verspinnbares Protein mit einer Sequenzidentität von wenigstens etwa 50%, wie z.B. wenigstens 60, 70, 80, 90, 95, 96, 97, 98 oder 99%.For example, the amphiphilic self-assembling protein is a silk protein, such as, in particular, a spider silk protein, preferably a C16 protein (see SEQ ID NO: 2,); or a spinnable protein derived from these proteins having a sequence identity of at least about 50%, e.g. at least 60, 70, 80, 90, 95, 96, 97, 98 or 99%.
Andere bevorzugte intrinsisch entfaltete, amphiphile selbstassemblierende Proteine sind das R16-Protein, umfassend eine Aminosäuresequenz gemäß SEQ ID NO: 4 oder das S16-Protein, umfassend eine Aminosäuresequenz gemäß SEQ ID NO: 6; oder ein von diesen Proteinen abgeleitetes verspinnbares Protein mit einer Sequenzidentität von wenigstens etwa 60%, wie z.B. wenigstens 70, 80, 90, 95, 96, 97, 98 oder 99%.Other preferred intrinsically unfolded amphiphilic self-assembling proteins are the R16 protein comprising an amino acid sequence of SEQ ID NO: 4 or the S16 protein comprising an amino acid sequence of SEQ ID NO: 6; or a spinnable protein derived from these proteins having a sequence identity of at least about 60%, e.g. at least 70, 80, 90, 95, 96, 97, 98 or 99%.
Unter "Seidenproteine" werden solche Proteine verstanden, die hoch repetitive Aminosäuresequenzen enthalten und im Tier in einer flüssigen Form gespeichert werden und bei deren Sekretion durch Scherung oder Verspinnen Fasern entstehen (
Besonders geeignete Proteine sind Spinnenseidenproteine, die in ihrer ursprünglichen Form aus Spinnen isoliert werden konnten.Particularly suitable proteins are spider silk proteins which could be isolated in their original form from spiders.
Ganz besonders geeignete Proteine sind Seidenproteine, die aus der "Major Ampullate"-Drüse von Spinnen isoliert werden konnten.Especially suitable proteins are silk proteins that could be isolated from the spider's "major ampullate" gland.
Bevorzugte Seidenproteine sind ADF3 und ADF4 aus der der "Major Ampullate"-Drüse von Araneus diadematus (
Ebenso geeignete Proteine sind natürliche oder synthetische Proteine, die sich von natürlichen Seidenproteinen ableiten und welche unter Verwendung gentechnologischer Arbeitsmethoden heterolog in prokaryontischen oder eukaryontischen Expressionssystemen hergestellt wurden. Nichtlimitierende Beispiele für prokaryontische Expressionsorganismen sind Escherichia coli, Bacillus subtilis, Bacillus megaterium, Corynebacterium glutamicum u.a.. Nichtlimitierende Beispiele für eukaryontische Expressionsorganismen sind He-fen, wie Saccharomyces cerevisiae, Pichia pastoris u.a., filamentöse Pilze, wie Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans, Trichoderma reesei, Acremonium chrysogenum u.a., Säugetierzellen, wie Hela-Zellen, COS-Zellen, CHO-Zellen u.a., Insektenzellen, wie Sf9-Zellen, MEL-Zellen u.a..Also suitable proteins are natural or synthetic proteins derived from natural silk proteins and which, using genetic engineering techniques, are heterologous in prokaryotic or eukaryotic expression systems were manufactured. Nonlimiting examples of prokaryotic expression organisms are Escherichia coli, Bacillus subtilis, Bacillus megaterium, Corynebacterium glutamicum and others. Nonlimiting examples of eukaryotic expression organisms are yeasts such as Saccharomyces cerevisiae, Pichia pastoris and others, filamentous fungi such as Aspergillus niger, Aspergillus oryzae, Aspergillus nidulans, Trichoderma reesei, Acremonium chrysogenum and others, mammalian cells such as Hela cells, COS cells, CHO Cells, etc., insect cells, such as Sf9 cells, MEL cells and others.
Besonders bevorzugt sind synthetische Proteine, welche auf Wiederholungseinheiten von natürlichen Seidenproteinen basieren. Neben den synthetischen repetitiven Seidenprotein-Sequenzen können diese zusätzlich eine oder mehrere natürliche nicht-repetitve Seidenprotein-Sequenzen enthalten (
Unter den synthetischen Seidenproteinen bevorzugt für die Formulierung von Wirkstoffen mittels Spinnverfahren sind synthetische Spinnenseidenproteine, welche auf Wiederholungseinheiten von natürlichen Spinnenseidenproteinen basieren. Neben den synthetischen repetitiven Spinnenseidenprotein-Sequenzen können diese zusätzlich eine oder mehrere natürliche nicht-repetitve Spinnenseidenprotein-Sequenzen enthalten.Among the synthetic silk proteins preferred for the formulation of drugs by means of spinning processes are synthetic spider silk proteins which are based on repeating units of natural spider silk proteins. In addition to the synthetic repetitive spider silk protein sequences, these may additionally contain one or more natural non-repetitive spider silk protein sequences.
Unter den synthetischen Spinnenseidenproteinen ist bevorzugt das sog. C16-Protein zu nennen (
Neben der in SEQ ID NO:2 dargestellten Polypeptidsequenz sind auch besonders funktionale Äquivalente, funktionale Derivate und Salze dieser Sequenz bevorzugt.In addition to the polypeptide sequence shown in SEQ ID NO: 2, particularly functional equivalents, functional derivatives and salts of this sequence are also preferred.
Weiterhin sind synthetische Proteine bevorzugt, welche auf Wiederholungseinheiten von natürlichen Seidenproteinen kombiniert mit Sequenzen von Insektenstrukturproteinen wie dem Resilin (
Unter den Kombinationsproteinen aus Seidenproteinen und Resilinen besonders bevorzugt sind die R16- und S16-Proteine. Diese Proteine haben die in SEQ ID NO: 4 und SEQ ID NO: 6 dargestellten Polypeptidsequenzen.Particularly preferred among the combination proteins of silk proteins and resilins are the R16 and S16 proteins. These proteins have the polypeptide sequences shown in SEQ ID NO: 4 and SEQ ID NO: 6.
Neben der in SEQ ID NO: 4 und SEQ ID NO: 6 dargestellten Polypeptidsequenzen sind auch besonders funktionale Äquivalente, funktionale Derivate und Salze dieser Sequenzen bevorzugt.In addition to the polypeptide sequences shown in SEQ ID NO: 4 and SEQ ID NO: 6, particularly functional equivalents, functional derivatives and salts of these sequences are also preferred.
Unter "funktionalen Äquivalenten" versteht man erfindungsgemäß insbesondere auch Mutanten, welche in wenigstens einer Sequenzposition der oben genannten Aminosäuresequenzen eine andere als die konkret genannte Aminosäure aufweisen aber trotzdem die Eigenschaft zur Verpackung von Effektstoffen besitzt. "Funktionale Äquivalente" umfassen somit die durch eine oder mehrere Aminosäure-Additionen, - Substitutionen, -Deletionen und/oder-Inversionen erhältlichen Mutanten, wobei die genannten Veränderungen in jeglicher Sequenzposition auftreten können, solange sie zu einer Mutante mit dem erfindungsgemäßen Eigenschaftsprofil führen. Funktionale Äquivalenz ist insbesondere auch dann gegeben, wenn die Reaktivitätsmuster zwischen Mutante und unverändertem Polypeptid qualitativ übereinstimmen.According to the invention, "functional equivalents" are understood in particular also to mean mutants which are present in at least one sequence position of the abovementioned amino acid sequences have another than the specifically mentioned amino acid but still has the property for packaging effect substances. "Functional equivalents" thus include the mutants obtainable by one or more amino acid additions, substitutions, deletions, and / or inversions, which changes can occur in any sequence position as long as they result in a mutant having the property profile of the invention. Functional equivalence is especially given when the reactivity patterns between mutant and unchanged polypeptide are qualitatively consistent.
"Funktionale Äquivalente" im obigen Sinne sind auch "Präkursoren" der beschriebenen Polypeptide sowie "funktionale Derivate" und "Salze" der Polypeptide."Functional equivalents" in the above sense are also "precursors" of the described polypeptides as well as "functional derivatives" and "salts" of the polypeptides.
"Präkursoren" sind dabei natürliche oder synthetische Vorstufen der Polypeptide mit oder ohne die gewünschte biologische Aktivität."Precursors" are natural or synthetic precursors of the polypeptides with or without the desired biological activity.
Beispiele für geeignete Aminosäuresubstitutionen sind folgender Tabelle zu entnehmen:
Unter dem Ausdruck "Salze" versteht man sowohl Salze von Carboxylgruppen als auch Säureadditionssalze von Aminogruppen der erfindungsgemäßen Proteinmoleküle. Salze von Carboxylgruppen können in an sich bekannter Weise hergestellt werden und umfassen anorganische Salze, wie zum Beispiel Natrium-, Calcium-, Ammonium-, Eisen- und Zinksalze, sowie Salze mit organischen Basen, wie zum Beispiel Aminen, wie Triethanolamin, Arginin, Lysin, Piperidin und dergleichen. Säureadditionssalze, wie zum Beispiel Salze mit Mineralsäuren, wie Salzsäure oder Schwefelsäure und Salze mit organischen Säuren, wie Essigsäure und Oxalsäure sind ebenfalls Gegenstand der Erfindung.The term "salts" means both salts of carboxyl groups and acid addition salts of amino groups of the protein molecules according to the invention. Salts of carboxyl groups can be prepared in a manner known per se and include inorganic salts such as sodium, calcium, ammonium, iron and zinc salts, as well as salts with organic bases such as amines such as triethanolamine, arginine, lysine , Piperidine and the like. Acid addition salts, such as, for example, salts with mineral acids, such as hydrochloric acid or sulfuric acid, and salts with organic acids, such as acetic acid and oxalic acid, are likewise provided by the invention.
"Funktionale Derivate" erfindungsgemäßer Polypeptide können an funktionellen Aminosäure-Seitengruppen oder an deren N- oder C-terminalen Ende mit Hilfe bekannter Techniken ebenfalls hergestellt werden. Derartige Derivate umfassen beispielsweise aliphatische Ester von Carbonsäuregruppen, Amide von Carbonsäuregruppen, erhältlich durch Umsetzung mit Ammoniak oder mit einem primären oder sekundären Amin; N-Acylderivate freier Aminogruppen, hergestellt durch Umsetzung mit Acylgruppen; oder O-Acylderivate freier Hydroxygruppen, hergestellt durch Umsetzung mit Acylgruppen."Functional derivatives" of polypeptides of the invention may also be produced at functional amino acid side groups or at their N- or C-terminal end by known techniques. Such derivatives include, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups prepared by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups prepared by reaction with acyl groups.
Erfindungsgemäß mit umfasste "funktionale Äquivalente" sind Homologe zu den hierin konkret offenbarten Proteinen/Polypeptiden. Diese besitzen wenigstens 60%, wie z.B. 70, 80 oder 85%, wie z.B. 90, 91, 92, 93, 94, 95, 96, 97, 98 oder 99%, Identität zu einer der konkret offenbarten Aminosäuresequenzen.Included in the invention with "functional equivalents" are homologs to the specific proteins / polypeptides disclosed herein. These have at least 60%, e.g. 70, 80 or 85%, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity to one of the specifically disclosed amino acid sequences.
Unter "Identität" zwischen zwei Sequenzen wird insbesondere die Identität der Reste über die jeweils gesamte Sequenzlänge verstanden, insbesondere die Identität, die durch Vergleich mit Hilfe der Vector NTI Suite 7.1 (Vector NTI Advance 10.3.0, Invitrogen Corp.) (bzw. Software der Firma Informax (USA) unter Anwendung der Clustal Methode (Higgins DG, Sharp PM. Fast and sensitive multiple sequence alignments on a microcomputer.
Zur Herstellung der erfindungsgemäßen beschichteten Proteinfasern können die genannten Proteine auch in Mischung mit einem oder mehreren Polymeren eingesetzt werden, z. B als Dispergierungsmittel oder Verdicker für die spinnbare Lösung. Sofern die Proteine in Mischung mit einem oder mehreren Polymeren eingesetzt werden, sind den Mischungsverhältnissen dabei grundsätzlich keine Grenzen gesetzt, üblicherweise umfassen solche Mischungen aber 10 bis 99 Gew.-%, bevorzugt 50 bis 99 Gew.-%, besonders bevorzugt 80 bis 99 Gew.-%, Protein und 1 bis 90 Gew.-%, bevorzugt 1 bis 50 Gew.-%, besonders bevorzugt 1 bis 20 Gew.-%, eines oder mehrerer Polymerer, wobei die Gew.-% jeweils bezogen sind auf das Gesamtgewicht aus Protein und Polymer und zusammen 100 Gew.-% ergeben.To produce the coated protein fibers according to the invention, the said proteins can also be used in admixture with one or more polymers, for. B as a dispersant or thickener for the spinnable solution. Provided the proteins are used in mixture with one or more polymers, the mixing ratios are basically no limits, but usually such mixtures include 10 to 99 wt .-%, preferably 50 to 99 wt .-%, particularly preferably 80 to 99 wt. -%, protein and 1 to 90 wt .-%, preferably 1 to 50 wt .-%, particularly preferably 1 to 20 wt .-%, of one or more polymers, wherein the wt .-% are each based on the total weight of Protein and polymer and together give 100 wt .-%.
Der Begriff "Polymere" umfasst dabei sowohl Homo- als auch Copolymere, ausgenommen Proteine. Als Copolymere kommen sowohl statistische als auch alternierende Systeme, Blockcopolymere oder Pfropfcopolymere in Frage. Der Begriff Copolymere umfasst Polymere, die aus zwei oder mehr verschiedenen Monomeren aufgebaut sind, oder aber bei denen sich der Einbau mindestens eines Monomers in die Polymerkette auf verschiedene Art und Weise realisieren lässt, wie es z.B. bei den Stereoblockcopolymeren der Fall ist. Es können auch Abmischungen von Homo- und Copolymeren eingesetzt werden. Die Homo- und Copolymere können miteinander mischbar oder nicht mischbar sein. Die für die erfindungsgemäßen Verfahren geeigneten Polymere können synthetischen Ursprungs sein, es können aber auch natürlich vorkommende Polymere, beispielsweise auf Polysaccharidbasis, sein. Geeignete Polymere sind beispielsweise Polyvinylalkohol, Poly-N-vinylpyrrolidon, Polyvinylformamid, Polyethylenoxid, Polyvinylamin, Polyvinylacetat, Polyacrylsäure, Polyacrylsäureester, Polyacrylamid, Polyaccharide wie Cellulose, Celluloseether wie z.B. Methylcellulose (mit einem Substitutionsgrad von 3 bis 40 %), Ethylcellulose, Butylcellulose, Hydroxymethylcellulosen; Hydroxyethylcellulosen; Hydroxypropylcellulosen, Isopropylcellulose, Celluloseester wie z.B. Celluloseacetat, Stärken, modifizierte Stärken wie z.B. Methylether-Stärke, Alginat.The term "polymers" encompasses both homopolymers and copolymers, with the exception of proteins. Suitable copolymers are both random and alternating systems, block copolymers or graft copolymers. The term copolymers encompasses polymers which are made up of two or more different monomers or in which the incorporation of at least one monomer into the polymer chain can be realized in various ways, e.g. in the case of stereo block copolymers. Blends of homopolymers and copolymers can also be used. The homo- and copolymers may be miscible or immiscible with each other. The polymers which are suitable for the processes according to the invention can be of synthetic origin, but they can also be naturally occurring polymers, for example based on polysaccharides. Suitable polymers include, for example, polyvinyl alcohol, poly-N-vinylpyrrolidone, polyvinylformamide, polyethylene oxide, polyvinylamine, polyvinyl acetate, polyacrylic acid, polyacrylic acid esters, polyacrylamide, polyaccharides such as cellulose, cellulose ethers such as e.g. Methylcellulose (with a degree of substitution of from 3 to 40%), ethylcellulose, butylcellulose, hydroxymethylcelluloses; hydroxyethylcelluloses; Hydroxypropylcelluloses, isopropylcellulose, cellulose esters, e.g. Cellulose acetate, starches, modified starches, e.g. Methyl ether starch, alginate.
Geeignete, dem Fachmann bekannte Verfahren zum Herstellen von Proteinfasern des genannten Durchmessers aus Lösung und Dispersion sind beispielsweise in
Da die Löslichkeiten der Proteine in Wasser aber oft nicht ausreichend sind und die Methoden zur Herstellung von wässrigen Proteinlösungen mehrere komplexe Stufen enthalten (unter anderem Dialyse), bieten sich in diesen Fällen zur Herstellung von Fasern bevorzugt Lösungen in organischen Lösungsmitteln, beispielsweise Essigsäure oder insbesondere Ameisensäure, an.Suitable methods known to the person skilled in the art for producing protein fibers of the stated diameter from solution and dispersion are described, for example, in US Pat
However, since the solubilities of the proteins in water are often insufficient and the methods for producing aqueous protein solutions contain several complex stages (inter alia dialysis), solutions in organic solvents, for example acetic acid or especially formic acid, are preferred in these cases for producing fibers , at.
Im Rahmen der vorliegenden Erfindung bevorzugte, dem Fachmann bekannte Verfahren zum Herstellen von Proteinfasern des genannten Durchmessers aus Lösung sind Elektrospinn- oder Zentrifugenspinnverfahren, insbesondere Elektrospinnverfahren. Verfahren zum Elektrospinnen sind beispielsweise in
Die beim Elektrospinnen einzusetzende Lösung kann auf alle dem Fachmann bekannten Arten elektroversponnen werden.
In einer bevorzugten Ausführungsform des Elektrospinnens wird die zu verspinnende Lösung in ein elektrisches Feld mit der Stärke von im Allgemeinen zwischen 0,01 bis 10 kV/cm, bevorzugt zwischen 1 und 6 kV/cm und besonders bevorzugt zwischen 2 und 4 kV/cm, eingebracht, indem sie aus einer oder mehreren Kanülen unter geringem Druck ausgepresst wird. Sobald die elektrischen Kräfte die Oberflächenspannung der Tropfen an der Kanülenspitze übersteigen, erfolgt der Massentransport in Form eines Jets auf die gegenüberliegende Elektrode. Das ggf. vorliegende Lösungsmittel verdampft im Zwischenelektrodenraum und der proteinhaltige Feststoff liegt dann in Form von Fasern auf der Gegenelektrode vor. Das Spinnen kann in beiden vertikalen Richtungen (von unten nach oben und von oben nach unten) und in horizontaler Richtung erfolgen.
In einer weiteren bevorzugten Ausführung des Elektrospinnverfahrens wird eine cylinder-basierte Vorrichtung, z.B. Nanospider der Fa. Elmarco (Czech Rep.), eingesetzt. Die eingesetzte Lösung befindet sich in einem Behälter, in dem eine Metallwalze permanent rotiert bzw. die Spinnformulierung wird auf die Walze mit separater Einrichtung dosiert. Die Walze kann glatt, strukturiert oder mit Metalldrähten versehen sein. Dabei befindet sich ein Teil der Formulierung beständig auf der Walzenoberfläche. Das elektrische Feld zwischen der Walze und der Gegenelektrode (oberhalb der Walze) bewirkt, dass sich aus der Formulierung erst flüssige Jets ausbilden, die dann auf dem Weg zur Gegenelektrode ggf. vorhandenes Lösungsmittel verlieren bzw. die Schmelze erstarrt. Ein Nanofaservlies (Faserflächengebilde) entsteht auf dem Substrat (z.B. aus Polypropylen, Polyester oder Cellulose), das zwischen den beiden Elektroden vorbeigeführt wird. Das elektrische Feld hat im Allgemeinen eine Stärke zwischen 0,01 bis 10 kV/cm, bevorzugt zwischen 1 und 6 kV/cm und besonders bevorzugt zwischen 2 und 4 kV/cm. Insbesondere hat das elektrische Feld in dieser Ausführungsform eine Stärke von 2,1 kV/cm (82 kV bei 25 cm Elektrodenabstand). Das Spinnen kann in beiden vertikalen Richtungen (von unten nach oben und von oben nach unten) und in horizontaler Richtung erfolgen.The solution to be used in electrospinning can be electrospun in any manner known to those skilled in the art.
In a preferred embodiment of the electrospinning, the solution to be spun is placed in an electric field with a thickness of generally between 0.01 and 10 kV / cm, preferably between 1 and 6 kV / cm and particularly preferably between 2 and 4 kV / cm, introduced by being squeezed out of one or more cannulas under low pressure. As soon as the electrical forces exceed the surface tension of the drops at the cannula tip, the mass transport in the form of a jet takes place on the opposite electrode. The possibly present solvent evaporates in the interelectrode space and the proteinaceous solid is then present in the form of fibers on the counter electrode. Spinning can be done in both vertical directions (bottom to top and top to bottom) and in horizontal direction.
In a further preferred embodiment of the electrospinning process, a cylinder-based device, for example Nanospider from Elmarco (Czech Rep.), Is used. The solution used is in a container in which a metal roller rotates permanently or the spin formulation is metered onto the roller with a separate device. The roll can be smooth, structured or provided with metal wires. In this case, part of the formulation is resistant to the roll surface. The electric field between the roller and the counterelectrode (above the roller) causes only liquid jets to form from the formulation, which then lose any solvent present or solidify the melt on the way to the counterelectrode. A nanofiber nonwoven fabric (fibrous web) is formed on the substrate (eg polypropylene, polyester or cellulose), which is passed between the two electrodes. The electric field generally has a strength between 0.01 to 10 kV / cm, preferably between 1 and 6 kV / cm and more preferably between 2 and 4 kV / cm. In particular, in this embodiment, the electric field has a magnitude of 2.1 kV / cm (82 kV at 25 cm electrode spacing). Spinning can be done in both vertical directions (bottom to top and top to bottom) and in horizontal direction.
Der Lösung oder Dispersion des Proteins können Additive zugegeben werden, um beispielsweise die Viskosität oder Oberflächenspannung zu verändern, wodurch sich bei den erfindungsgemäßen Verfahren z.B. die Faserbildung oder Fasermorphologie gezielt beeinflussen läßt. Bevorzugte Additive sind dem Fachmann bekannte und in der Literatur beschriebene Verdicker und Tenside.Additives may be added to the solution or dispersion of the protein to alter, for example, the viscosity or surface tension, resulting in e.g. selectively influence the fiber formation or fiber morphology. Preferred additives are thickeners and surfactants known to the person skilled in the art and described in the literature.
In einer bevorzugten Ausführungsform der Erfindung können der Lösung oder Dispersion des Proteins ein oder mehrere Wirkstoffe zugesetzt werden, die auf einen lebenden Organismus gezielt eine spezifische Wirkung, insbesondere eine pharmakologische, agrochemische, medizinische oder kosmetische Wirkung, entfalten. Bei diesen Wirkstoffen kann es sich um Pharmawirkstoffe, kosmetische Effektstoffe, agrochemische Wirkstoffe (Fungizide, Herbizide, Insektizide), Nahrungs- oder Futtermittelzusätze, biologische Wirkstoffe (Peptide, Wachstumsfaktoren, Bakterien) oder Kombination von mehreren dieser Wirkstoffe handeln. Die Art oder Formulierung der Wirkstoffe, ihre einzusetzenden Mengen und Konzentrationen sowie die gezielte spezifische Wirkung im lebenden Organismus sind dem Fachmann als solche bekannt und in der Literatur beschrieben (s. beispielsweise
Ziel des Zusatzes der genannten Wirkstoffe ist, daß diese nach der in der Folge noch beschriebenen Applikation der erfindungsgemäßen beschichteten Proteinfasern oder Faserflächengebilde an oder auf lebenden Organismen freigesetzt bzw. abgegeben werden, und an oder in dem lebenden Organismus gezielt eine gewünschte spezifische Wirkung entfalten.In a preferred embodiment of the invention, it is possible to add to the solution or dispersion of the protein one or more active substances which have a targeted effect on a living organism, in particular a pharmacological, agrochemical, medicinal or cosmetic effect. These active substances may be active pharmaceutical ingredients, cosmetic effect substances, agrochemical active substances (fungicides, herbicides, insecticides), food or feed additives, biological active substances (peptides, growth factors, bacteria) or a combination of several of these active substances. The type or formulation of the active ingredients, their amounts and concentrations to be used as well as the targeted specific action in the living organism are known to those skilled in the art as such and described in the literature (see, for example
The aim of the addition of the active substances mentioned is that they are released or released after the application of the coated protein fibers or fiber fabrics according to the invention on or on living organisms, and specifically develop a desired specific action on or in the living organism.
Die nach den genannten Verfahren aus Lösung oder Dispersion eines Proteins herstellbaren Fasern haben in der Regel einen Durchmesser im Bereich von 10 nm bis 10 µm, bevorzugt von 20 nm bis 5 µm, besonders bevorzugt von 50 nm bis 2 µm.The fibers which can be prepared from the solution or dispersion of a protein by the abovementioned processes generally have a diameter in the range from 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, particularly preferably from 50 nm to 2 .mu.m.
Erfindungswesentlich ist, daß diese Fasern während oder nach ihrer Herstellung mit einem 2-Cyanacrylsäureester kontaktiert werden.Essential to the invention is that these fibers are contacted during or after their preparation with a 2-cyanoacrylic acid ester.
Geeignete 2-Cyanacrylsäureester, die dem Fachmann grundsätzlich bekannt und in der Literatur beschrieben sind, sind beispielsweise Methyl-, Ethyl-, n-Butyl-, Octyl-, Allyl-, oder Methoxyethylester der 2-Cyanacrylsäure, insbesondere Ethyl-2-cyanacrylat.Suitable 2-cyanoacrylic acid esters, which are generally known to the person skilled in the art and are described in the literature, are, for example, methyl, ethyl, n-butyl, octyl, allyl or methoxyethyl esters of 2-cyanoacrylic acid, in particular ethyl 2-cyanoacrylate.
Die Kontaktierung der Proteinfasern kann erfindungsgemäß erfolgen, indem die Fasern während ihrer Herstellung einer Atmosphäre ausgesetzt sind, die gasförmige 2-Cyanacrylsäureester enthält. Der Partialdruck der 2-Cyanacrylsäureester in der Gasphase ist dabei gleich oder kleiner als der Dampfdruck des eingesetzten 2-Cyanacrylsäureesters bei der jeweiligen Verarbeitungstemperatur. Bei druckloser Verfahrensführung liegt der Partialdruck der eingesetzten 2-Cyanacrylsäureester in der Regel im Bereich von 1 mbar bis 1 bar, bevorzugt im Bereich von 50 mbar bis 800 mbar, besonders bevorzugt im Bereich von 100 mbar bis 500 mbar. Bei einer Druckfahrweise können die Partialdrücke der eingesetzten 2-Cyanacrylsäureester auch deutlich über diesen Werten liegen.The contacting of the protein fibers can be carried out according to the invention by exposing the fibers to an atmosphere containing gaseous 2-cyanoacrylates during their production. The partial pressure of 2-cyanoacrylates in the gas phase is equal to or less than the vapor pressure of the 2-cyanoacrylic ester used at the respective processing temperature. In non-pressurized process control, the partial pressure of the 2-cyanoacrylic esters used is generally in the range of 1 mbar to 1 bar, preferably in the range of 50 mbar to 800 mbar, more preferably in the range of 100 mbar to 500 mbar. In a printing procedure, the partial pressures of the 2-cyanoacrylic acid esters used can also be significantly higher than these values.
Bevorzugt erfolgt die Kontaktierung der Proteinfasern mit gasförmigem 2-Cyanacrylsäureester, indem die Fasern nach ihrer Herstellung einer Atmosphäre ausgesetzt sind, die gasförmige 2-Cyanacrylsäureester enthält. D.h. es werden in einem ersten Schritt die Proteinfasern nach den oben beschriebenen Verfahren hergestellt, und erst in einem zweiten separaten Schritt erfolgt die Kontaktierung der Proteinfasern mit gasförmigem 2-Cyanacrylsäureester. Der Vorteil dieser Variante besteht darin, daß die temperaturabhängigen Dampfdrücke der 2-Cyanacrylsäureester unabhängig von der Temperatur der Proteinfaserherstellung gewählt werden können. Bei druckloser Verfahrensführung liegt der Partialdruck der eingesetzten 2-Cyanacrylsäureester in der Regel im Bereich von 1 mbar bis 1 bar, bevorzugt im Bereich von 50 mbar bis 800 mbar, besonders bevorzugt im Bereich von 100 mbar bis 500 mbar. Bei einer Druckfahrweise können die Partialdrücke der eingesetzten 2-Cyanacrylsäureester auch deutlich über diesen Werten liegen.The contacting of the protein fibers with gaseous 2-cyanoacrylic acid ester is preferably carried out by exposing the fibers to an atmosphere containing gaseous 2-cyanoacrylic acid esters after their preparation. That In a first step, the protein fibers are prepared according to the methods described above, and only in a second separate step is the contacting of the protein fibers with gaseous 2-cyanoacrylic acid ester. The advantage of this variant is that the temperature-dependent vapor pressures of 2-cyanoacrylates can be chosen independently of the temperature of the protein fiber production. In non-pressurized process control, the partial pressure of the 2-cyanoacrylic esters used is generally in the range of 1 mbar to 1 bar, preferably in the range of 50 mbar to 800 mbar, more preferably in the range of 100 mbar to 500 mbar. In a printing procedure, the partial pressures of the 2-cyanoacrylic acid esters used can also be significantly higher than these values.
Die Kontaktierung der Proteinfasern mit gasförmigem 2-Cyanacrylsäureester sowohl während, als auch nach ihrer Herstellung erfolgt üblicherweise über einen Zeitraum von 1 s bis 60 min, bevorzugt von 10 s bis 30 min,besonders bevorzugt von 1 min bis 10 min.The contacting of the protein fibers with gaseous 2-cyanoacrylic acid both during and after their preparation is usually carried out over a period of 1 s to 60 min, preferably from 10 s to 30 min, more preferably from 1 min to 10 min.
In einer weiteren Ausführungsform der Erfindung kann die Kontaktierung der Proteinfasern mit 2-Cyanacrylsäureester auch erfolgen, indem die 2-Cyanacrylsäureester bereits der Lösung oder Dispersion des Proteins zugesetzt werden, aus der die Proteinfasern hergestellt werden (selbstverständlich ist diese Ausführungsform nicht möglich, wenn die Inhaltsstoffe der Lösung oder Dispersion chemisch mit den 2-Cyanacrylsäureestern reagieren oder ihre Polymerisation hervorrufen, was beispielsweise bei wäßrigen Lösungen der Fall ist). Die Konzentration der 2-Cyanacrylsäureester in der Lösung oder Dispersion liegt bei dieser Ausführungsform der Erfindung üblicherweise im Bereich von 0,1 bis 10 Gew.-%, bevorzugt von 0,5 bis 5 Gew.-%, besonders bevorzugt von1 bis 5 Gew.-%, jeweils bezogen auf das Gesamtgewicht der Lösung oder Dispersion.In a further embodiment of the invention, the contacting of the protein fibers with 2-cyanoacrylic esters can also be effected by adding the 2-cyanoacrylic acid esters already to the solution or dispersion of the protein from which the protein fibers are produced (of course, this embodiment is not possible if the ingredients the solution or dispersion chemically react with the 2-cyanoacrylates or cause their polymerization, which is the case for example with aqueous solutions). The concentration of 2-cyanoacrylic acid ester in the solution or dispersion in this embodiment of the invention is usually in the range of 0.1 to 10 wt .-%, preferably from 0.5 to 5 wt .-%, particularly preferably from 1 to 5 wt. -%, in each case based on the total weight of the solution or dispersion.
In einer weiteren Ausführungsform der Erfindung kann die Kontaktierung der Proteinfasern mit 2-Cyanacrylsäureester auch erfolgen, indem die Fasern nach ihrer Herstellung mit einer Lösung enthaltend die 2-Cyanacrylsäureester behandelt werden. Geeignete Lösungsmittel für 2-Cyanacrylsäureester sind beispielsweise Aceton oder 2-Butanon. Die Konzentration der 2-Cyanacrylsäureester in dieser Lösung liegt bei dieser Ausführungsform der Erfindung üblicherweise im Bereich von 0,1 bis 10 Gew.-%, bevorzugt von 0,5 bis 5 Gew.-%, besonders bevorzugt von1 bis 5 Gew.-%, jeweils bezogen auf das Gesamtgewicht der Lösung. Die Temperatur, bei der die Kontaktierung erfolgt, liegt üblicherweise im Bereich von 5 bis 90 °C, bevorzugt von 15 bis 50 °C, besonders bevorzugt von 18 bis 30 °C. Die Kontaktierung der Proteinfasern mit der Lösung der 2-Cyanacrylsäureester erfolgt in der Regel über einen Zeitraum von 1 s bis 60 min, bevorzugt von 10 s bis 30 min, besonders bevorzugt von 1 min bis 10 min.In a further embodiment of the invention, the contacting of the protein fibers with 2-cyanoacrylic acid ester can also be effected by treating the fibers after their preparation with a solution containing the 2-cyanoacrylic acid esters. suitable Solvents for 2-cyanoacrylic acid esters are, for example, acetone or 2-butanone. The concentration of 2-cyanoacrylic acid esters in this solution is usually in the range from 0.1 to 10% by weight, preferably from 0.5 to 5% by weight, particularly preferably from 1 to 5% by weight, in this embodiment of the invention. , in each case based on the total weight of the solution. The temperature at which the contacting takes place is usually in the range from 5 to 90 ° C., preferably from 15 to 50 ° C., particularly preferably from 18 to 30 ° C. The contacting of the protein fibers with the solution of the 2-cyanoacrylic esters is generally carried out over a period of 1 s to 60 min, preferably from 10 s to 30 min, more preferably from 1 min to 10 min.
Von den beschriebenen Ausführungsformen der erfindungsgemäßen Verfahren ist die Kontaktierung der Proteinfasern mit 2-Cyanacrylsäureester bevorzugt, bei der die Fasern nach oder während ihrer Herstellung einer Atmosphäre ausgesetzt werden, die gasförmige 2-Cyanacrylsäureester enthält.Of the described embodiments of the method according to the invention, the contacting of the protein fibers with 2-cyanoacrylic acid ester is preferred, in which the fibers are exposed after or during their production to an atmosphere containing gaseous 2-cyanoacrylic acid esters.
Die beschriebenen Beschichtungen der Proteinfasern mit 2-Cyanacrylsäureester sind nicht auf die Fasern als solche beschränkt, sondern können entsprechend auch an den aus den Proteinfasern gebildeten Faserflächengebilden durchgeführt werden.The described coatings of the protein fibers with 2-cyanoacrylic acid ester are not limited to the fibers as such, but can also be carried out accordingly on the fibrous webs formed from the protein fibers.
Die im Verlauf der erfindungsgemäßen Verfahren herstellbaren Proteinfasern haben einen Durchmesser im Bereich von 10 nm bis 10 µm, bevorzugt von 20 nm bis 5 µm, besonders bevorzugt von 50 nm bis 2 µm. Die Länge der Fasern hängt vom Verwendungszweck ab und beträgt in der Regel 50 µm bis hin zu mehreren Kilometern.The protein fibers which can be produced in the course of the process according to the invention have a diameter in the range from 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, particularly preferably from 50 nm to 2 .mu.m. The length of the fibers depends on the purpose and is usually 50 microns to several kilometers.
Durch die Kontaktierung der Proteinfasern oder der Faserflächengebilde mit 2-Cyanacrylsäureester scheidet sich monomeres 2-Cyanacrylat ab und wird zu Poly-2-cyanacrylaten polymerisiert. Die Abscheidung erfolgt in der Regel in Form einer auf der Proteinfaser haftenden, besonders bevorzugt vollständigen, Beschichtung. Die Beschichtung kann aber auch teilweise erfolgen, d.h. die Oberfläche der Proteinfasern wird nicht vollständig beschichtet. Je nach Morphologie der Fasern ist es auch möglich, daß die gebildeten Poly-2-cyanacrylate nicht oder nur zum Teil in Form einer Beschichtung an der Faser haften, sondern stattdessen oder auch in der Faser oder an der Faser haften.By contacting the protein fibers or the fiber fabrics with 2-cyanoacrylic ester, monomeric 2-cyanoacrylate precipitates and is polymerized to poly-2-cyanoacrylates. The deposition is usually carried out in the form of an adhering to the protein fiber, particularly preferably complete, coating. The coating can also be partial, i. E. the surface of the protein fibers is not completely coated. Depending on the morphology of the fibers, it is also possible that the poly-2-cyanoacrylates formed are not or only partially adhere to the fiber in the form of a coating, but instead adhere to or in the fiber or on the fiber.
Die erfindungsgemäßen beschichteten Proteinfasern sind nach den erfindungsgemäßen Verfahren herstellbar. Bevorzugte erfindungsgemäße beschichtete Proteinfasern umfassend Proteinfasern mit einem Durchmesser im Bereich von 10 nm bis 10 µm, bevorzugt von 20 nm bis 5 µm, besonders bevorzugt von 50 nm bis 2 µm, und eine auf den Proteinfasern haftende Beschichtung aus Poly-2-Cyanacrylsäureester, wobei die Dicke der Beschichtung besonders bevorzugt im Bereich von 1 bis 200 nm, insbesondere von 10 bis 100 nm, liegt.The coated protein fibers according to the invention can be prepared by the processes according to the invention. Preferred inventive coated protein fibers comprising protein fibers having a diameter in the range of 10 nm to 10 .mu.m, preferably from 20 nm to 5 .mu.m, more preferably from 50 nm to 2 .mu.m, and a coating of poly-2-cyanoacrylic acid ester adhering to the protein fibers the thickness of the coating is particularly preferably in the range from 1 to 200 nm, in particular from 10 to 100 nm.
Die erfindungsgemäßen beschichteten Proteinfasern eignen sich insbesondere zur Herstellung von Faserflächengebilden. Die Herstellung der Faserflächengebilde kann entweder schon im gleichen Verfahrensschritt wie die Herstellung der Proteinfasern erfolgen, beispielsweise wie oben beschrieben bei der direkten Herstellung von Faserflächengebilden durch Elektrospinnen, oder in einem separaten Verfahrensschritt nach dem Fachmann bekannten und in der Literatur beschriebenen Verfahren im Anschluß an die Herstellung der erfindungsgemäßen beschichteten Proteinfasern.The coated protein fibers according to the invention are particularly suitable for the production of fibrous sheets. The preparation of the fiber fabrics can be carried out either in the same process step as the production of protein fibers, for example as described above in the direct production of fiber fabrics by electrospinning, or in a separate process step known in the art and described in the literature following the preparation the coated protein fibers of the invention.
Diese erfindungsgemäßen Faserflächengebilde können in zahlreichen verschiedenen Anwendungsbereichen eingesetzt werden, zum Beispiel zur Herstellung von Nonwovens oder Vliesen, insbesondere Vliesen zur Anwendung in kosmetischen Erzeugnissen, Textilien, insbesondere Haushaltstextilien, Reinigungsprodukten, Medizinprodukten (wie Wundabdeckungen oder Gesichtsmasken), Hygieneprodukte wie Windeln, Inkontinenz-Produkte, Slipeinlagen, Monatsbinden, Tampons, Pads zur Haut- und Gesichtspflege und dergleichen, Zellkulturträger. Die genannten Gegenstände können ganz oder nur teilweise aus den Faserflächengebilden bestehen, z. B in Form von Beschichtungen oder/und Bestandteilen. Bevorzugt werden die erfindungsgemäßen Faserflächengebilde als Filter und medizinische Träger verwendet.
Besonders bevorzugte Faserflächengebilde werden verwendet als Wundbehandlungsund Wundversorgungsprodukte, Wundauflagen, Pflaster, Tamponaden, Wundkleber, Bandagen, Verbandmaterialien. Sie können beispielsweise verwendet werden zur oberflächlichen Abdeckung kleinerer Wunden, wie Schnittwunden, oder größerer Wunden, wie diabetische Wunden, Geschwüren, wie Druckgeschwüre, Operationswunden, Brandwunden, Ekzeme und dergleichen. Beispielsweise können erfindungsgemäße Faserflächengebilde zum Einsatz gelangen bei der Behandlung von blutenden oder nichtblutenden Wunden oder Verletzungen im Bereich der Haut, der Augen, der Ohren, der Nase, der Mundhöhle, der Zähne, sowie im Körperinneren, wie Operation im Intestinalbereich (Magen, Darm, Leber, Nieren, Harnwege), Thorax (Herz, Lunge), Genitalbereich, Schädel, Muskulatur; bei der Behandlung und Nachsorge von Wunden im Zusammenhang mit der Transplantation von Geweben, Gefäßen oder Organen.These fibrous sheets according to the invention can be used in numerous different fields of application, for example for the production of nonwovens or nonwovens, in particular nonwovens for use in cosmetic products, textiles, in particular household textiles, cleaning products, medical products (such as wound dressings or face masks), hygiene products such as diapers, incontinence products , Panty liners, sanitary napkins, tampons, skin and facial pads, and the like, cell culture carriers. The objects mentioned may consist wholly or only partially of the fiber fabrics, z. B in the form of coatings and / or components. The fibrous sheets according to the invention are preferably used as filters and medical carriers.
Particularly preferred fiber sheets are used as wound care and wound care products, wound dressings, plasters, tamponades, wound dressings, bandages, dressings. For example, they can be used to superficially cover minor wounds such as cuts or larger wounds such as diabetic wounds, ulcers such as pressure sores, surgical wounds, burns, eczema, and the like. For example, fibrous sheets according to the invention can be used in the treatment of bleeding or non-bleeding wounds or injuries in the area of the skin, the eyes, the ears, the nose, the oral cavity, the teeth, as well as in the interior of the body, such as surgery in the intestinal region (stomach, intestine, Liver, kidneys, urinary tract), thorax (heart, lungs), genital area, skull, musculature; in the treatment and aftercare of wounds related to the transplantation of tissues, vessels or organs.
Die nach den erfindungsgemäßen Verfahren herstellbaren beschichteten Proteinfasern sowie Faserflächengebilde besitzen gegenüber bekannten Nanofasern eine verbesserte Wasser- bzw. Feuchtigkeitsbeständigkeit, d.h. sie weisen unter Wasser- bzw. Feuchtigkeitseinwirkung eine verringerte Löslichkeit, Quellung und/oder Veränderung der mechanischen Eigenschaften und/oder der Durchflußeigenschaften und/oder der Faserstruktur und/oder ein verbessertes Zersetzungs- bzw. Abbauverhalten auf. Die Verwendung organischer Lösungsmittel wird bei den erfindungsgemäßen Verfahren wenn möglich weitgehend vermieden. Ein weiterer Vorteil der erfindungsgemäßen beschichteten Proteinfasern besteht darin, daß polymerisierte 2-Cyanacrylsäureester aus medizinischer bzw. toxikologischer Sicht unbedenklich sind (s. beispielsweise
Die Erfindung wird nachstehend anhand von Beispielen näher erläutert.The invention will be explained in more detail below with reference to examples.
Es zeigen:
- Fig. 1
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel V-1 erhaltenen Proteinfasern (Protein S16, nicht kontaktiert, vor Wasserbehandlung)
- Fig. 2
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel V-1 erhaltenen Proteinfasern (Protein S16, nicht kontaktiert, nach Wasserbehandlung)
- Fig. 3
- eine rasterelektronenmikroskopische Aufnahme der in
Beispiel 1 erhaltenen Proteinfasern (Protein S16, kontaktiert mit Ethyl-2-cyanacrylat, vor Wasserbe- handlung) - Fig. 4
- eine rasterelektronenmikroskopische Aufnahme der in
Beispiel 1 erhaltenen Proteinfasern (Protein S16, kontaktiert mit Ethyl-2-cyanacrylat, nach Wasserbe- handlung) - Fig. 5
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel 2 erhaltenen Proteinfasern (Protein S16, kontaktiert mit einer Lösung von Ethyl-2- cyanacrylat, vor Wasserbehandlung)
- Fig. 6
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel 2 erhaltenen Proteinfasern (Protein S16, kontaktiert mit einer Lösung von Ethyl-2- cyanacrylat, nach Wasserbehandlung)
- Fig. 7
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel V-3 erhaltenen Proteinfasern (Protein R16, nicht kontaktiert, vor Wasserbehandlung)
- Fig. 8
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel V-3 erhaltenen Proteinfasern (Protein R16, nicht kontaktiert, nach Wasserbehandlung)
- Fig. 9
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel 3 erhaltenen Proteinfasern (Protein R16, kontaktiert mit Ethyl-2-cyanacrylat, vor Wasserbe- handlung)
- Fig. 10
- eine rasterelektronenmikroskopische Aufnahme der in Beispiel 3 erhaltenen Proteinfasern (Protein R16, kontaktiert mit Ethyl-2-cyanacrylat, nach Wasserbe- handlung)
- Fig. 11 A-D
- Photographische Widergabe der R16-Proteinfasern, wie sie in Vergleichs- beispiel V-4a und Beispielen 4 b-d nach 24-stündiger Inkubation im Protei- nase K enthaltenden Puffer anfielen (
Fig. 11A : nicht mit Ethyl-2- cyanacrylat kontaktierte R16-Proteinfasern;Fig. 11 B: 20 Sekunden mit Ethyl-2-cyanacrylat behandelte R16-Proteinfasern;Fig. 11 C: 60 Sekunden mit Ethyl-2-cyanacrylat behandelte R16-Proteinfasern;Fig. 11 D: 120 Se- kunden mit Ethyl-2-cyanacrylat behandelte R16-Proteinfasern) - Fig. 12
- Absorptionsphotometrische Bestimmung der Proteinfaser-Abbauprodukte in den nach enzymatischem Abbau gemäß Beispielen V-4a und 4 b-d er- haltenen Überständen
- Fig. 1
- a scanning electron micrograph of the protein fibers obtained in Example V-1 (protein S16, not contacted, before water treatment)
- Fig. 2
- a scanning electron micrograph of the protein fibers obtained in Example V-1 (protein S16, not contacted, after water treatment)
- Fig. 3
- a scanning electron micrograph of the protein fibers obtained in Example 1 (protein S16, contacted with ethyl 2-cyanoacrylate, before water treatment)
- Fig. 4
- a scanning electron micrograph of the protein fibers obtained in Example 1 (protein S16, contacted with ethyl 2-cyanoacrylate, after water treatment)
- Fig. 5
- a scanning electron micrograph of the protein fibers obtained in Example 2 (protein S16, contacted with a solution of ethyl 2-cyanoacrylate, before water treatment)
- Fig. 6
- a scanning electron micrograph of the protein fibers obtained in Example 2 (protein S16, contacted with a solution of ethyl 2-cyanoacrylate, after water treatment)
- Fig. 7
- a scanning electron micrograph of the protein fibers obtained in Example V-3 (protein R16, not contacted, before water treatment)
- Fig. 8
- a scanning electron micrograph of the protein fibers obtained in Example V-3 (protein R16, not contacted, after water treatment)
- Fig. 9
- a scanning electron micrograph of the protein fibers obtained in Example 3 (protein R16, contacted with ethyl 2-cyanoacrylate, before water treatment)
- Fig. 10
- a scanning electron micrograph of the protein fibers obtained in Example 3 (protein R16, contacted with ethyl 2-cyanoacrylate, after water treatment)
- Fig. 11 AD
- Photographic reproduction of the R16 protein fibers, as obtained in Comparative Example V-4a and Examples 4 bd after incubation in the proteinase K incubation for 24 hours (
Fig. 11A non-ethyl cyanoacrylate contacted R16 protein fibers;Fig. 11 B: ethyl 2-cyanoacrylate treated R16 protein fibers for 20 seconds;Fig. 11 C: Ethyl 2-cyanoacrylate-treated R16 protein fibers for 60 seconds;Fig. 11 D: 120 seconds with ethyl 2-cyanoacrylate treated R16 protein fibers) - Fig. 12
- Absorption photometric determination of the protein fiber degradation products in the supernatants obtained after enzymatic degradation according to Examples V-4a and 4 bd
Die in den Beispielen beschriebenen Proteinfasern wurden nach den folgenden entweder spitzenbasierten oder walzenbasierten Elektrospinnverfahren hergestellt. Weitergehende spezifische Angaben werden bei den einzelnen Beispielen genannt.The protein fibers described in the Examples were prepared by the following either tip-based or roller-based electrospinning techniques. Further specific details are given in the individual examples.
Zur Herstellung der Proteinfasern nach dem spitzenbasierten Elektrospinnverfahren wurde eine Vorrichtung eingesetzt, bei der eine mit einem Pol einer Spannungsquelle verbundenen Kapillardüse zum Verdüsen der Proteindispersion oder -lösung verwendet wird. Gegenüber dem Ausgang der Kapillardüse ist in einem Abstand von etwa 20 cm eine mit dem anderen Pol der Spannungsquelle verbundene quadratische Gegenelektrode angeordnet, die als Kollektor für die gebildeten Fasern fungiert. Während des Betriebs der Vorrichtung wird an den Elektroden eine Spannung zwischen 15 kV und 35 kV eingestellt und die Proteindispersion oder -lösung unter einem geringen Druck durch die Kapillardüse ausgetragen. Aufgrund der durch das starke elektrische Feld von 0,9 bis 2 kV/cm erfolgenden elektrostatischen Aufladung der Proteindispersion oder -lösung entsteht ein auf die Gegenelektrode gerichteter Materialstrom, der sich auf dem Wege zur Gegenelektrode unter Faserbildung verfestigt, infolge dessen sich auf der Gegenelektrode Fasern mit Durchmessern im Mikro- und Nanometerbereich abscheiden.To prepare the protein fibers by the tip-based electrospinning method, an apparatus has been used in which a capillary nozzle connected to one pole of a power source is used to atomize the protein dispersion or solution. Opposite the outlet of the capillary nozzle, a square counterelectrode connected to the other pole of the voltage source is arranged at a distance of about 20 cm, which acts as a collector for the fibers formed. During operation of the device, a voltage between 15 kV and 35 kV is set at the electrodes and the protein dispersion or solution is discharged through the capillary nozzle under a low pressure. Due to the electrostatic charge of the protein dispersion or solution due to the strong electric field of 0.9 to 2 kV / cm, a material flow directed towards the counterelectrode solidifies on the way to the counterelectrode with fiber formation, resulting in fibers on the counterelectrode with diameters in the micron and nanometer range.
Zur Herstellung der Proteinfasern nach dem walzenbasierten Elektrospinnverfahren wurde eine Vorrichtung eingesetzt, bei der sich eine als Elektrode geschaltete gezackte Walze in einem Behälter mit Proteindispersion oder -lösung dreht (Nanospider-Apparatur der Firma Elmarco). Die Gegenelektrode befindet sich oberhalb der Walze. Die Proteindispersion oder -lösung geriet bei jeder Drehung der Walze in das starke elektrische Feld und mehrere Materialströme wurden gebildet. Die Fasern wurden auf einem ruhenden Trägervlies abgeschieden.To prepare the protein fibers by the roll-based electrospinning method, an apparatus has been used in which a serrated roller connected as an electrode rotates in a protein dispersion or solution container (Nanospider Elmarco apparatus). The counter electrode is located above the roller. The protein dispersion or solution got into the strong electric field with each rotation of the roll and several streams of material were formed. The fibers were deposited on a resting carrier fleece.
Die erfindungsgemäßen beschichteten Proteinfasern wurden entweder mit gasförmigen oder in einem Lösungsmittel gelösten 2-Cyanacrylsäureestern kontaktiert. Weitergehende spezifische Angaben werden bei den einzelnen Beispielen genannt.The coated protein fibers according to the invention were contacted either with gaseous or dissolved in a solvent 2-Cyanacrylsäureestern. Further specific details are given in the individual examples.
Die gemäß den Beispielen und Vergleichsbeispielen hergestellten Proteinfasern und erfindungsgemäßen beschichteten Proteinfasern wurden zur Ermittlung der Wasser- bzw. Feuchtigkeitsbeständigkeit für einen Zeitraum von 24 h in ruhendes Wasser mit einer Temperatur von 23°C eingebracht. Nach anschließender Trocknung wurden elektronen- oder lichtmikroskopische Aufnahmen angefertigt. Durch Vergleich per Augenschein mit entsprechenden elektronen- oder lichtmikroskopischen Aufnahmen der identischen Proteinfaserproben vor der Wasserbehandlung läßt sich erkennen, ob und wie stark sich die Fasern, ihre Morphologie oder Gefügestruktur unter der Wassereinwirkung verändert hat, d.h. wie wasser- bzw. feuchtigkeitsbeständig die Fasern sind.The protein fibers and coated protein fibers according to the invention prepared according to the examples and comparative examples were introduced into quiescent water at a temperature of 23 ° C. for a period of 24 hours to determine the resistance to water or moisture. After subsequent drying, electron or light micrographs were taken. By comparing them visually with corresponding electron or light micrographs of the identical protein fiber samples prior to water treatment, it can be seen whether and how much the fibers, their morphology or microstructure has changed under the action of water, i. how water- or moisture-resistant the fibers are.
Für die Herstellung von verspinnbaren S16-Protein-Lösungen wurden S16-Protein-Microbeads genutzt. Diese können wie in
Die Herstellung des S16-Proteins erfolgt biotechnologisch unter Verwendung plasmidhaltiger Escherichia coli Expressionsstämme (dabei kamen Plasmidvektoren bzw. E. coli-Produktionsstämme zum Einsatz, welche kodierende DNA-Sequenzen für das S16-Protein enthielten). Design und Klonierung des S16-Proteins sind analog zu
The production of the S16 protein is carried out biotechnologically using plasmid-containing Escherichia coli expression strains (plasmid vectors or E. coli production strains were used which contained coding DNA sequences for the S16 protein). Design and cloning of the S16 protein are analogous to
Nach der Zellernte wurde das Pellet in 20mM 3-(-N-Morpholino)propanesulfonic acid (MOPS) pH 7,0 resuspendiert (5L Puffer pro Kilogramm Feuchtmasse). Anschließend erfolgte der Zell-Aufschluss unter Verwendung eines Micofluidizer M-110EH (Microfluidics, US) bei Drücken von 1200 bis 1300 bar. Nach Sedimentation enthielt das Pellet nach Aufschluss neben den "Inclusion Bodies" noch Zelltrümmer und Membranbestandteile, welche durch zwei Waschschritte entfernt wurden. In einem ersten Waschschritt wurde das Pellet in 2,5 Volumen Tris-Puffer (50 mM Tris/HCl, 0,1 % Triton X-100, pH 8,0) resuspendiert und anschließend der verbleibende Feststoff durch Zentrifugation sedimentiert. Ein zweiter Waschschritt erfolgte unter Verwendung von Tris-Puffer (50 mM Tris/HCl, 5mM EDTA, pH 8,0). Das abermals nach Sedimentation erhaltene Pellet war nahezu frei von Membran- und Zelltrümmern.After cell harvesting, the pellet was resuspended in 20 mM 3 - (- N-morpholino) propanesulfonic acid (MOPS) pH 7.0 (5 L buffer per kilogram wet weight). Subsequently, cell digestion was carried out using a Micofluidizer M-110EH (Microfluidics, US) at pressures of 1200 to 1300 bar. After sedimentation, the pellet contained after digestion in addition to the "inclusion bodies" cell debris and membrane components, which were removed by two washing steps. In a first washing step, the pellet was resuspended in 2.5 volumes Tris buffer (50 mM Tris / HCl, 0.1% Triton X-100, pH 8.0), and then the remaining solid was sedimented by centrifugation. A second wash was performed using Tris buffer (50 mM Tris / HCl, 5 mM EDTA, pH 8.0). The pellet, once again obtained after sedimentation, was almost free of membrane and cell debris.
Die gereinigten "Inclusion Bodies" wurden in Guanidiniumthiocyanat (Roth, Germany) gelöst, wobei pro 1 g Pellet (Feuchtmasse) 1,6 g Guanidiniumthiocyanat zugegeben wurden. Die "Inclusion Bodies" lösten sich unter Rühren bei leichter Erwärmung (50°C). Zur Abtrennung evtl. vorhandener nicht-löslicher Bestandteile wurde anschließend noch eine Zentrifugation durchgeführt. Um eine wässrige S16-Proteinlösung zu erhalten, wurde dann eine 16-stündige Dialyse gegen 5 mM Kaliumphosphatpuffer (pH 8,0) durchgeführt (Verdünnungsfaktor der Dialyse: 200).The purified "inclusion bodies" were dissolved in guanidinium thiocyanate (Roth, Germany), 1.6 g guanidinium thiocyanate being added per 1 g pellet (wet mass). The inclusion bodies were dissolved with gentle heating (50 ° C.) with stirring. To separate off any non-soluble constituents, a centrifugation was then carried out. In order to obtain an aqueous S16 protein solution, dialysis was then carried out for 16 hours against 5 mM potassium phosphate buffer (pH 8.0) (dilution factor of dialysis: 200).
Verunreinigende E. coli-Proteine bildeten bei der Dialyse Aggregate, welche durch Zentrifugation abgetrennt werden konnten. Die erhaltene Proteinlösung wies eine Reinheit von ∼95% S16-Protein auf.Contaminating E. coli proteins formed aggregates on dialysis, which could be separated by centrifugation. The resulting protein solution had a purity of ~95% S16 protein.
Um eine lagerfähige Form des Proteins herzustellen, wurde die wässrige Proteinlösung durch Fällung zu Protein-Microbeads weiterverarbeitet. Zur Herstellung von S16-Protein-Microbeads wurde die wässrige S16-Proteinlösung mit 0,25 Volumenteilen einer 4-molaren Ammoniumsulfatlösung versetzt. Unter Einwirkung des Ammoniumsulfats assemblieren die Proteinmonomere zu kugelförmigen Gebilden, welche hier als Microbeads bezeichnet werden. Die Microbeads wurden durch Zentrifugation abgetrennt, drei Mal mit destilliertem Wasser gewaschen und anschließend gefriergetrocknet.To prepare a storable form of the protein, the aqueous protein solution was processed by precipitation to protein microbeads. To prepare S16 protein microbeads, the aqueous S16 protein solution was admixed with 0.25 parts by volume of a 4 molar ammonium sulfate solution. Under the action of the ammonium sulfate, the protein monomers assemble into spherical structures, which are referred to here as microbeads. The microbeads were separated by centrifugation, washed three times with distilled water and then freeze-dried.
Für die Herstellung einer verspinnbaren Lösung wurden 10 Gewichtsteile S16-Protein-Microbeads in 90 Gewichtsteilen wasserfreier Ameisensäure (Reinheit 99,9 Gew.-%) gelöst.For the production of a spinnable solution, 10 parts by weight of S16 protein microbeads were dissolved in 90 parts by weight of anhydrous formic acid (purity 99.9% by weight).
Diese Proteinlösung wurde nach dem walzenbasierten Elektrospinnverfahren zu Proteinfasern verarbeitet, wobei folgende Verfahrensparameter gewählt wurden:
Die so erhaltenen Proteinfasern (Beispiel V-1) werden in
Ein Teil der in Beispiel V-1 erhaltenen Proteinfasern wurde wie oben beschrieben bzgl. der Wasser- bzw. Feuchtigkeitsbeständigkeit getestet.
Ein anderer Teil der in Beispiel V-1 erhaltenen Proteinfasern wurde wie folgt mit Ethyl-2-Cyanacrylat kontaktiert:Another portion of the protein fibers obtained in Example V-1 was contacted with ethyl 2-cyanoacrylate as follows:
0,2 g Ethyl-2-Cyanacrylat der Fa. Sigma Aldrich wurden in ein Glasfläschchen mit einem Volumen von 10 ml gegeben und anschließend bei einer Temperatur von 150 - 170°C in die Gasphase gebracht, d.h. verdampft. Anschließend wurde das Substrat mit den in Beispiel V-1 erhaltenen Proteinfasern für einen Zeitraum von 1 Minute in dieser Gasphase kontaktiert. Die so erhaltenen beschichteten Proteinfasern (Beispiel 1) werden in
Ein Teil der in Beispiel 1 erhaltenen beschichteten Proteinfasern wurde wie oben beschrieben bzgl. der Wasser- bzw. Feuchtigkeitsbeständigkeit getestet.
Ergebnis: Während sich die nicht mit 2-Cyanacrylat kontaktierten Proteinfasern in ihrer Faserstruktur deutlich veränderten, blieb die Faserstruktur der mit 2-Cyanacrylat kontaktierten beschichteten Proteinfasern weitgehend erhalten.Result: While the non-2-cyanoacrylate-contacted protein fibers changed significantly in their fiber structure, the fiber structure of the 2-cyanoacrylate contacted coated protein fibers remained largely intact.
Als Protein wurde das in Beispielen V-1 und 1 beschriebene Protein S16 eingesetzt und auf die ebenfalls in Beispielen V-1 und 1 beschriebene Art zu Proteinfasern verarbeitet.The protein S16 described in Examples V-1 and 1 was used as the protein and processed into protein fibers in the manner also described in Examples V-1 and 1.
Die so erhaltenen Proteinfasern wurden wie folgt mit Ethyl-2-Cyanacrylat kontaktiert:The protein fibers thus obtained were contacted with ethyl 2-cyanoacrylate as follows:
0,1 g Ethyl-2-Cyanacrylat wurden in 9,9 g Toluol gelöst. Anschließend wurde das Substrat mit den in Beispiel 2 erhaltenen Proteinfasern für einen Zeitraum von 10 Sekunden mit dieser toluolischen Ethyl-2-Cyanacrylat Lösung kontaktiert und abschließend getrocknet. Die so erhaltenen beschichteten Proteinfasern (Beispiel 2) werden in
Ein Teil der in Beispiel 2 erhaltenen beschichteten Proteinfasern wurde wie oben beschrieben bzgl. der Wasser- bzw. Feuchtigkeitsbeständigkeit getestet.
Ergebnis: Während sich die nicht mit 2-Cyanacrylat kontaktierten Proteinfasern in ihrer Faserstruktur deutlich veränderten, blieb die Faserstruktur der mit 2-Cyanacrylat kontaktierten beschichteten Proteinfasern weitgehend erhalten.Result: While the non-2-cyanoacrylate-contacted protein fibers changed significantly in their fiber structure, the fiber structure of the 2-cyanoacrylate contacted coated protein fibers remained largely intact.
Die Herstellung von verspinnbaren R16-Protein-Lösungen erfolgte analog zu der in Beispielen V-1 und 1 beschriebenen Herstellung der S16-Protein-Lösungen.The preparation of spinnable R16 protein solutions was carried out analogously to the preparation of the S16 protein solutions described in Examples V-1 and 1.
Diese R16-Proteinlösung wurde nach dem walzenbasierten Elektrospinnverfahren zu Proteinfasern verarbeitet, wobei folgende Verfahrensparameter gewählt wurden:
Die so erhaltenen Proteinfasern (Beispiel V-3) werden in
Ein Teil der in Beispiel V-3 erhaltenen Proteinfasern wurde wie oben beschrieben bzgl. der Wasser- bzw. Feuchtigkeitsbeständigkeit getestet.
Ein anderer Teil der in Beispiel V-3 erhaltenen Proteinfasern wurde wie folgt mit Ethyl-2-Cyanacrylat kontaktiert:Another portion of the protein fibers obtained in Example V-3 was contacted with ethyl 2-cyanoacrylate as follows:
0,2 g Ethyl-2-Cyanacrylat der Fa. Sigma Aldrich wurden in ein Glasfläschchen mit einem Volumen von 10 ml gegeben und anschließend bei einer Temperatur von 150 - 170°C in die Gasphase gebracht, d.h. verdampft. Anschließend wurde das Substrat mit den in Beispiel V-3 erhaltenen Proteinfasern für einen Zeitraum von 1 Minute in dieser Gasphase kontaktiert. Die so erhaltenen beschichteten Proteinfasern (Beispiel 3) werden in
Ein Teil der in Beispiel 3 erhaltenen beschichteten Proteinfasern wurde wie oben beschrieben bzgl. der Wasser- bzw. Feuchtigkeitsbeständigkeit getestet.
Ergebnis: Während die Faserstruktur der nicht mit 2-Cyanacrylat kontaktierten Proteinfasern vollständig zerstört wurde, blieb die Faserstruktur der mit 2-Cyanacrylat kontaktierten beschichteten Proteinfasern weitgehend erhalten.Result: While the fiber structure of the non-2-cyanoacrylate-contacted protein fibers was completely destroyed, the fiber structure of the 2-cyanoacrylate-contacted coated protein fibers remained largely intact.
R16-Proteinfasern wurden wie in Beispiel V-3 beschrieben hergestellt.R16 protein fibers were prepared as described in Example V-3.
Anschließend wurde ein Teil dieser Proteinfasern wie in Beispiel 3 beschrieben mit Ethyl-2-Cyanacrylat kontaktiert, wobei jedoch drei separate Ansätze mit Kontaktzeiten von 20 Sekunden, 60 Sekunden bzw. 120 Sekunden realisiert wurden.Subsequently, some of these protein fibers were contacted with ethyl 2-cyanoacrylate as described in Example 3, but with three separate batches having contact times of 20 seconds, 60 seconds and 120 seconds, respectively.
Anschließend wurden von den nicht mit Ethyl-2-Cyanacrylat kontaktierten Proteinfasern (Beispiel V-4a) und jedem der in den drei mit Ethyl-2-Cyanacrylat kontaktierten Ansätzen (Beispiele 4 b-d) erhaltenen Proteinfasergebilde jeweils 2-3 cm2 große Stücke in 1,5 ml Eppendorf-Reaktionsgefäße überführt und mit 1 ml 5 mM Kaliumphosphatpuffer versetzt. Dabei enthielt der Kaliumphosphatpuffer 1,2 AU Proteinase K (Quiagen, Deutschland). Die Ansätze wurden bei 23 °C und 700 Upm in einem Thermomixer (Fa. Eppendorf) inkubiert.
Nach definierten Zeitabständen wurden jeweils 20 µl Probe aus dem Ansatz gemäß Beispiel V-4a und den drei Ansätzen gemäß Beispielen 4 b-d entnommen und eventuell enthaltener Feststoff abzentrifugiert. Durch absorptionsphotometrische Messung (280 nm) am Überstand (d.h. an der nach der Zentrifugation erhaltenen klaren Flüssigphase) wurde anschließend der Anteil an Proteinabbauprodukten (Peptiden) bestimmt.Subsequently, of the protein fibers not contacted with ethyl 2-cyanoacrylate (Example V-4a) and each of the protein fiber structures obtained in the three ethyl 2-cyanoacrylate contacted approaches (Examples 4 bd) were each 2-3 cm 2 pieces in FIG , Transferred 5 ml Eppendorf tubes and mixed with 1 ml of 5 mM potassium phosphate buffer. The potassium phosphate buffer contained 1.2 AU proteinase K. (Quiagen, Germany). The mixtures were incubated at 23 ° C. and 700 rpm in a thermomixer (Eppendorf).
After defined time intervals, in each
Die nicht mit Ethyl-2-Cyanacrylat kontaktierten R16-Proteinfasern (Beispiel V-4a) zeigten in den Proteinase K-Ansätzen visuell schon nach 120 min deutliche Abbau- bzw. Auflösungserscheinungen. Nach 24 h waren die nicht mit Ethyl-2-Cyanacrylat kontaktierten R16-Proteinfasern (Beispiel V-4a) visuell fast vollständig abgebaut (
Auch die o. g. absorptionsphotometrische Bestimmung der Überstände zeigte, dass mit Ethyl-2-Cyanacrylat kontaktierte R16-Proteinfasern deutlich langsamer durch Proteinase K abgebaut werden als nicht-kontaktierte. Überstände aus den Proteinase K enthaltenden Ansätzen gemäß Beispielen 4 b-d wiesen im für die Abbaukinetik betrachteten Zeitverlauf bis 480 min eine deutlich schwächere Absorption auf als der gemäß Beispiel V-4a mit Proteinase K erhaltene Überstand der nicht mit Ethyl-2-Cyanacrylat kontaktierte R16-Proteinfasern (
Die Beispiele belegen, daß die nach den erfindungsgemäßen Verfahren herstellbaren beschichteten Proteinfasern sowie Faserflächengebilde gegenüber bekannten Nanofasern eine verbesserte Wasser- bzw. Feuchtigkeitsbeständigkeit besitzen, d.h. sie weisen unter Wasser- bzw. Feuchtigkeitseinwirkung eine verringerte Löslichkeit, Quellung und/oder Veränderung der mechanischen Eigenschaften und/oder der Durchflußeigenschaften und/oder der Faserstruktur und/oder ein verbessertes Zersetzungs- bzw. Abbauverhalten auf. The examples show that the coated protein fibers and fiber fabrics produced by the process according to the invention have improved water or moisture resistance compared to known nanofibers, ie they have a reduced solubility, swelling and / or change in the mechanical properties under water or moisture. or the flow properties and / or the fiber structure and / or an improved decomposition or degradation behavior.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170024A EP2295630A1 (en) | 2009-09-11 | 2009-09-11 | Method for producing coated protein fibres |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170024A EP2295630A1 (en) | 2009-09-11 | 2009-09-11 | Method for producing coated protein fibres |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2295630A1 true EP2295630A1 (en) | 2011-03-16 |
Family
ID=41698412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP09170024A Ceased EP2295630A1 (en) | 2009-09-11 | 2009-09-11 | Method for producing coated protein fibres |
Country Status (1)
| Country | Link |
|---|---|
| EP (1) | EP2295630A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105209509A (en) * | 2013-05-16 | 2015-12-30 | 意大利学院科技基金会 | Process for the production of poly(cyanoacrylate) fibres |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB779502A (en) * | 1954-12-30 | 1957-07-24 | Courtaulds Ltd | Improvements in and relating to the production of artificial filaments, fibres, threads and the like |
| EP0490143A2 (en) * | 1990-12-13 | 1992-06-17 | United States Surgical Corporation | Method and apparatus for tipping sutures |
| WO2001080921A2 (en) * | 2000-04-20 | 2001-11-01 | Emory University | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| WO2005094911A2 (en) * | 2004-03-05 | 2005-10-13 | Oxford Biomaterials Limited | Composite materials |
-
2009
- 2009-09-11 EP EP09170024A patent/EP2295630A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB779502A (en) * | 1954-12-30 | 1957-07-24 | Courtaulds Ltd | Improvements in and relating to the production of artificial filaments, fibres, threads and the like |
| EP0490143A2 (en) * | 1990-12-13 | 1992-06-17 | United States Surgical Corporation | Method and apparatus for tipping sutures |
| WO2001080921A2 (en) * | 2000-04-20 | 2001-11-01 | Emory University | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| WO2005094911A2 (en) * | 2004-03-05 | 2005-10-13 | Oxford Biomaterials Limited | Composite materials |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105209509A (en) * | 2013-05-16 | 2015-12-30 | 意大利学院科技基金会 | Process for the production of poly(cyanoacrylate) fibres |
| CN105209509B (en) * | 2013-05-16 | 2017-05-10 | 意大利学院科技基金会 | Process for producing poly(cyanoacrylate) fibers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2042199B1 (en) | Bioresorbable wound dressings | |
| AT393795B (en) | COHERENT, POROESIC COLLAGEN FILM MATERIAL AND METHOD FOR THE PRODUCTION THEREOF | |
| Zhou et al. | Quaternized chitin/tannic acid bilayers layer-by-layer deposited poly (lactic acid)/polyurethane nanofibrous mats decorated with photoresponsive complex and silver nanoparticles for antibacterial activity | |
| EP2126166B1 (en) | Fiber matting | |
| RU2468129C2 (en) | Biopolymeric fibre, composition of forming solution for its obtaining, method of forming solution preparation, linen of biomedical purpose, biological bandage and method of wound treatment | |
| EP2609109A2 (en) | Method for producing highly concentrated solutions of self-assembling proteins | |
| DE3751938T2 (en) | ACID DECRISTALLIZATION OF HIGH CRYSTALLINE CHITOSAN OR PARTIAL TACETYLATED CHITINE | |
| EP2328567A2 (en) | Continuous fiber layer comprising an active substance on the basis of bio-polymers, the use thereof, and method for the production thereof | |
| CN103276472B (en) | Collagen/polyvinyl alcohol composite microspheres as well as preparation method and application thereof | |
| DE69826119T2 (en) | HETEROPOLYSACCHARIDE CONJUGATES, HALVINTERPENETRIEREN POLYSACCHARIDGELE AND METHOD FOR THE PRODUCTION THEREOF | |
| US20240216571A1 (en) | Chitosan superfine fiber systems | |
| Andrade et al. | Latex and natural rubber: processing techniques for biomedical applications | |
| WO2012055494A1 (en) | Nonwoven materials made of synthetic polymers and rotary spinning method for manufacturing same | |
| WO2010031862A9 (en) | Use of lyocell fibers and items comprising lyocell fibers | |
| Allafchian et al. | Design and characterization of Persian gum/polyvinyl alcohol electrospun nanofibrous scaffolds for cell culture applications | |
| EP2295630A1 (en) | Method for producing coated protein fibres | |
| DE19859611C2 (en) | Fibrin glue granules and process for their production | |
| WO2012175164A1 (en) | Stable aqueous protein solution or protein dispersion, method for the production of said stable aqueous solution or dispersion, and method for the production of molded articles or sheet material, impregnations or coatings from the stable aqueous protein solution or protein dispersion, and use thereof | |
| WO2018047905A1 (en) | ε-POLYLYSINE MICROFIBER AND FIBER STRUCTURE, AND METHOD FOR MANUFACTURING SAME | |
| WO2012175153A2 (en) | Stable aqueous protein solution or protein dispersion, method for the production of said stable aqueous solution or dispersion, and method for the production of molded articles or sheet material, impregnations, or coatings from the stable aqueous protein solution or protein dispersion, and use thereof | |
| EP2776512A1 (en) | Method for producing milk protein gels, -hydrogels, -hydrocolloides and -superabsorbers (milk protein gels) | |
| Raihan et al. | A Review of PEO (Polyethylene Oxide) Assisted Electrospinning of Chitosan: Innovation, Production, and Application. | |
| DE19841649A1 (en) | Production of solutions of fibrillar proteins, especially silk, comprises dissolving the protein in N-methylmorpholine N-oxide | |
| DE102006001773B3 (en) | Preparation of a molded protein composite comprises dispersing the protein in water and in aqueous solution of ionic liquid, applying the solution on a smooth plate and recovering the molded protein composite as foil/membrane | |
| WO2009098029A2 (en) | Wound dressing articles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20110402 |





















